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9ABSTRACT
Two major genes, BRCA1 and BRCA2, germline mutations of which predispose to both
breast and ovarian carcinoma, have been identified. At the time this study began, 11 distinct
germline mutations in BRCA1 and seven in BRCA2 had been described in Finnish breast and
breast-ovarian carcinoma families. Eleven of these 18 mutations had been detected in more
than one Finnish family, and they had been found to account for the vast majority of all
BRCA1/BRCA2 mutation-positive families identified in the screening of the entire coding
regions of the genes. The aims of the present study were to examine ancestral origins and
geographical distribution of families with recurrent Finnish BRCA1 and BRCA2 mutations, to
study breast and ovarian carcinoma phenotypes of Finnish BRCA1 and BRCA2 mutation
carriers, and to evaluate the prevalence of BRCA1 and BRCA2 founder mutations in Finnish
ovarian carcinoma patients and ovarian carcinoma families.
Haplotype analysis was used to study the origins of families with recurrent mutations,
and time from a common ancestor for the families was estimated by modifications of the
Luria-Delbrück equation. All BRCA1/BRCA2 mutation-positive families identified in Finland
were included in the phenotype analysis examining the distribution of ages at breast and
ovarian cancer diagnosis, and the proportion of ovarian carcinoma. The contribution of
BRCA1 and BRCA2 founder mutations to ovarian carcinoma was evaluated by studying the
prevalence of previously identified Finnish BRCA1 and BRCA2 germline mutations in
unselected ovarian carcinoma patients and in a population-based series of families with at
least two cases of ovarian carcinoma in first-degree relatives. In addition, a subset of ovarian
carcinoma patients was screened for novel BRCA1/BRCA2 germline mutations. The
relationship between mutation carrier status and personal and family history of breast and
ovarian carcinoma was studied by logistic regression analysis.
Haplotype analyses revealed that all carriers of the same recurrent BRCA1/BRCA2
mutation, except for those with the BRCA2 999del5 mutation, shared a common core
haplotype. In the 999del5 mutation-positive families, two distinct core haplotypes were seen.
The mutation-associated haplotypes shared by carriers of the same mutation indicate that
mutation alleles are identical by descent, i.e., founder mutations. The two 999del5 mutation-
associated haplotypes may be due to gene conversion, which is supported by the geographical
clustering of the families as well as by the population history of Finland. Finnish families
with one of the 999del5 mutation-associated haplotypes shared a four-marker (0.5 cM)
haplotype with Icelandic families with the same mutation, which may indicate a common
ancient origin for the Finnish and Icelandic 999del5 mutation-positive families. Nevertheless,
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distinct mutational events cannot be ruled out. Estimations of time from a common ancestor
for the Finnish families varied widely, ranging from 6 to 32 generations. For some mutations,
birthplaces of the parents and grandparents were clustered in a very restricted area, while for
other mutations, a wider distribution was seen. The high coverage of founder mutations of all
BRCA1/BRCA2 mutations in Finland and the narrow mutation spectra observed in certain
geographical areas have a significant impact on BRCA1/BRCA2 mutation testing in Finnish
breast and ovarian carcinoma families.
Analysis of breast and ovarian carcinoma phenotypes revealed that the proportion of
ovarian carcinoma was significantly higher in BRCA1 mutation-associated families than in
those with BRCA2 mutations. Moreover, in the BRCA1 mutation-positive families, the
proportion of ovarian carcinoma was significantly higher in families carrying mutations in
exon 11 as compared with those carrying mutations 3´ of this exon. For breast carcinoma, the
distribution of ages at diagnosis was similar in BRCA1 and BRCA2 mutation-positive
families, while for ovarian carcinoma, the mean age at diagnosis was significantly younger in
families with BRCA1 mutations.
In unselected ovarian carcinoma patients, the frequency of BRCA1 and BRCA2
mutations was 4.7% and 0.9%, respectively. No novel mutations were identified, and seven
founder mutations accounted for 12 of the 13 mutations detected. The most significant
predictor of a BRCA1 or BRCA2 mutation was presence of both breast and ovarian carcinoma
in the same patient. Moreover, family history of breast carcinoma was strongly related to
mutation carrier status. In Finnish ovarian carcinoma families, the BRCA1/BRCA2 mutation
frequency was 26%. All families with strong family history of ovarian carcinoma (i.e., three
affected cases) or early-onset (<50 years) breast carcinoma were mutation-positive, while all
families with later-onset breast carcinoma and most (9/11) families with two cases of ovarian
carcinoma only were mutation-negative. A combination of chance clustering of sporadic
cases, non-genetic familial factors and incomplete sensitivity of mutation detection may
account for BRCA1/BRCA2 mutation-negative ovarian carcinoma families. However,
unidentified ovarian cancer-susceptibility genes, possibly with low penetrance, may segregate
in some families.
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INTRODUCTION
Breast cancer is the most common and ovarian cancer the fourth most common cancer among
women in Finland, with 3578 and 522 new cases diagnosed in 1999, respectively [the Finnish
Cancer Registry (FCR), 2002]. Approximately 10% of all ovarian carcinomas and 7% of all
breast carcinomas are estimated to be associated with dominantly inherited germline
mutations in cancer-susceptibility genes (Claus et al., 1996). To date, two major genes,
BRCA1 and BRCA2, germline mutations of which predispose to both breast and ovarian
carcinoma, have been identified (Miki et al., 1994; Wooster et al., 1994). More than 1000
distinct germline alterations have been identified in each gene, most of them appearing
uniquely in a single family [the Breast Cancer Information Core (BIC) database]. However, in
several ethnic groups and populations, recurrent mutations have been described (Szabo and
King, 1997; Neuhausen, 1999). The proportion of unique versus recurrent BRCA1/BRCA2
mutations varies among populations, reflecting historical influences of migration, population
structure, and geographical and cultural isolation (Szabo and King, 1997). Germline
mutations of BRCA1 and BRCA2 confer a high risk of breast and ovarian cancer, although
risk estimates obtained from different studies are variable [Ford et al., 1994, 1998; Easton et
al., 1995; Thorlacius et al., 1998; the Breast Cancer Linkage Consortium (BCLC), 1999;
Anglian Breast Cancer Study Group (ABCSG), 2000; Antoniou et al., 2000, 2002; Satagopan
et al., 2001]. There is also evidence for a modifying effect of other genes as well as non-
genetic factors on the risks of breast and ovarian cancer in BRCA1 and BRCA2 mutation
carriers (Hopper et al., 1999; Antoniou et al., 2000, 2002; Nathanson and Weber, 2001).
Furthermore, the location of the mutation in BRCA1 and BRCA2 may influence breast and
ovarian carcinoma risks (Gayther et al., 1995, 1997b; Risch et al., 2001; Thompson and
Easton, 2001, 2002).
In the Finnish population, 11 recurrent mutations have been found to account for the
vast majority (84%) of BRCA1/BRCA2 mutations identified in the screening of the entire
coding regions of the genes (Vehmanen et al., 1997a, 1997b; Huusko et al., 1998). Therefore,
a reasonable estimate of the BRCA1/BRCA2 mutation burden in various Finnish study
populations can be achieved rapidly and cost-efficiently by screening samples for the known
Finnish BRCA1/BRCA2 mutations. In different populations, inherited mutations of BRCA1
and BRCA2 account for a varying fraction of hereditary breast and ovarian carcinoma (Szabo
and King, 1997). Only a small proportion of familial aggregation of breast carcinoma appears
to be explained by BRCA1 and BRCA2 germline mutations in most populations (Szabo and
King, 1997), and there is evidence that other still undiscovered breast cancer-susceptibility
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genes exist (Serova et al., 1997; Ford et al., 1998; Kainu et al., 2000; Antoniou et al., 2001;
Cui et al., 2001). BRCA1 and BRCA2 germline mutations may, however, be sufficient to
explain the majority of hereditary ovarian carcinoma (Gayther et al., 1999; Antoniou et al.,
2000). The aims of this thesis were thus to examine the ancestral origins and geographical
distribution of families with recurrent Finnish BRCA1 and BRCA2 mutations, to study breast
and ovarian carcinoma phenotypes of Finnish BRCA1 and BRCA2 mutation carriers, and to
evaluate the prevalence of BRCA1 and BRCA2 founder mutations in Finnish ovarian
carcinoma patients and ovarian carcinoma families.
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REVIEW OF THE LITERATURE
1 General features of ovarian carcinoma
Ovarian cancer is the sixth most common cancer among women world-wide (Parkin et al.,
1999). In Finland, 522 new cases of ovarian cancer were diagnosed in 1999, making it the
fourth most common cancer among women (the FCR, 2002). The cumulative incidence of
ovarian cancer by the age of 75 years is 1.4% (Auranen et al., 1996b).
Of all malignant ovarian tumours, carcinomas, i.e., tumours originating from the
surface epithelium of the ovary, account for approximately 90% (Russell, 1994; Holschneider
and Berek, 2000). Ovarian carcinoma is predominantly a disease of peri- and postmenopausal
women (Russell, 1994; Holschneider and Berek, 2000), and the mean age at diagnosis is 62
years (Auranen et al., 1996a). The most common histological subtypes of ovarian carcinoma
are serous, endometrioid, and mucinous carcinoma, representing 40–50%, 15–25%, and 5–
15% of all cases, respectively (Russell, 1994; Heintz et al., 2001). Less common histological
subtypes include clear cell carcinoma, undifferentiated carcinoma, transitional cell
carcinoma, malignant Brenner tumour, and malignant mixed epithelial tumour (Russell,
1994).
The overall prognosis of patients with ovarian carcinoma is poor, which is related to the
high proportion of women being diagnosed with advanced stage disease (stages III and IV)
(Heintz et al., 2001). Stage of disease at diagnosis according to the Fédération Internationale
de Gynécologie et d’Obstetrique (FIGO) staging system is one of the most significant
prognostic factors of the disease (Friedlander, 1998). The five-year survival rate for patients
with FIGO stage I, II, III, and IV tumours is 85–89%, 57–67%, 24–42%, and 12–17%,
respectively (Nguyen et al., 1993; Heintz et al., 2001). Other prognostic indicators include
histological type and grade, residual tumour size, performance status, and patient’s age
(Friedlander, 1998).
One of the strongest risk factors for the disease is a family history of ovarian and/or
breast cancer, and the risk depends on the number of affected first- and second-degree
relatives and their age at diagnosis (Schildkraut et al., 1989; Parazzini et al., 1992; Stratton et
al., 1998; Holschneider and Berek, 2000). Other factors associated with an increased risk
include infertility and nulliparity (Edmondson and Monaghan, 2001; Ness et al., 2002), while
factors associated with a decreased risk include multiparity, lactation, oral contraceptive use,
tubal ligation, and hysterectomy (Whittemore et al., 1992; Edmondson and Monaghan, 2001).
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2 General features of breast carcinoma
Breast cancer is the most frequently occurring cancer among women world-wide, comprising
21% of all female cancers (Parkin et al., 1999). In Finland, 3578 new breast cancer cases
were diagnosed in women and 14 in men in 1999 (the FCR, 2002). Incidence rates rise
rapidly with increasing age, but the rate of increase declines around menopause (Pike et al.,
1983; the FCR, 2002). Average age at diagnosis is 61 years (Dickman et al., 1999), and about
one in ten Finnish women will develop breast cancer during her lifetime (the FCR, 2002).
The majority of malignant breast tumours are carcinomas. Infiltrating ductal carcinoma
is by far the most common histological type of invasive breast carcinoma, accounting for
about 70% of all cases (Berg and Hutter, 1995). The five-year relative survival rate for
Finnish breast cancer patients is 80% (Dickman et al., 1999). However, the prognosis varies
widely between patients, and for those with localized disease, regional metastases, and distant
metastases, the five-year relative survival rates are 93%, 69%, and 22%, respectively
(Dickman et al., 1999).
The aetiology of breast cancer is closely linked to oestrogen, with a prolonged or
increased exposure being suggested to increase breast cancer risk (Pike et al., 1983;
Henderson and Feigelson, 1998). Many known risk factors for breast cancer are related to the
reproductive life of women: early age at menarche, late onset of menopause, late age at first
full-term pregnancy, and nulliparity (Henderson and Feigelson, 1998; McPherson et al., 2000;
Hulka and Moorman, 2001). A family history of breast cancer and/or ovarian cancer is one of
the strongest risk factors for the disease (Sattin et al., 1985; Schildkraut et al., 1989; Madigan
et al., 1995; Pharoah et al., 1997); the risk increases as the number of affected first- and
second-degree relatives increases and their age at diagnosis decreases, and if there are cases
of bilateral breast cancer among relatives (Sattin et al., 1985; Slattery and Kerber, 1993;
Pharoah et al., 1997). Other risk factors for breast cancer include exposure to ionizing
radiation, postmenopausal obesity, and history of atypical epithelial hyperplasia (McPherson
et al., 2000; Hulka and Moorman, 2001). Factors that confer protection consist of multiparity,
early age at first full-term pregnancy, lactation, and physical activity (Henderson and
Feigelson, 1998; Hulka and Moorman, 2001).
3 Genes involved in carcinogenesis
Carcinogenesis is a multistep process during which genetic and epigenetic alterations
accumulate in a cell, resulting in the progressive transformation of normal cells through steps
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of initiation, promotion, and progression into cancer cells. Genes involved in cancer affect the
normal functions of such cellular processes as cell proliferation and differentiation, apoptosis,
deoxyribonucleic acid (DNA) repair, genomic stability, senescense, cell-cell communication,
cell-matrix interactions, angiogenesis, tumour invasion, motility, and metastasis (Nowell,
1976; Compagni and Christofori, 2000; Hanahan and Weinberg, 2000; Evan and Vousden,
2001; Ponder, 2001). Three major groups of genes are known to be involved in cancer: proto-
oncogenes, classical tumour suppressor genes (also known as gatekeeper tumour suppressor
genes), and caretaker tumour suppressor genes (Weinberg, 1989; Kinzler and Vogelstein,
1997; Ponder, 2001). At present, around 30 tumour suppressor genes (TSGs) and over 100
proto-oncogenes have been identified (Futreal et al., 2001).
Proto-oncogenes are involved in the control of normal cell proliferation, apoptosis, and
differentiation, and their inappropriate activation may turn them into oncogenes. At the
cellular level, these genes are dominant, i.e., activation of one allele (gain-of-function) is
sufficient to give a growth advantage to the cell (Ponder, 2001). Conversely, gatekeeper and
caretaker TSGs act recessively at the cellular level, i.e., inactivation of both alleles (loss-of-
function) is required for an altered cell phenotype (Weinberg, 1989; Ponder, 2001). However,
recent evidence for haplo-insufficiency at some tumour suppressor gene loci, e.g., BRCA1,
BRCA2, PTEN, and STK11, exists (Fero et al., 1998; Kwabi-Addo et al., 2001; Buchholz et
al., 2002; Miyoshi et al., 2002). Gatekeeper TSGs act directly to prevent tumour growth by
suppressing proliferation, inducing apoptosis, or promoting differentiation, and their loss of
function is rate-limiting for a particular step in tumourigenesis, whereas caretaker TSGs act
indirectly to suppress neoplasia, and their inactivation leads to genetic instability which
results in a greatly increased mutation rate of all genes, including gatekeeper TSGs and proto-
oncogenes (Kinzler and Vogelstein, 1997). This sub-classification of TSGs has, however,
become arbitrary as some genes, including BRCA1, BRCA2, and TP53, have been shown to
have both gatekeeper and caretaker tumour suppressor functions (Macleod, 2000; Zheng et
al., 2000). Furthermore, a new class of TSGs has been proposed: landscapers that are
predicted to act by modulating the local stromal microenvironment such that the neoplastic
conversion of epithelia is promoted (Kinzler and Vogelstein, 1998; Liotta and Kohn, 2001).
4 Inherited predisposition to cancer
Most genetic alterations that lead to cancer are somatic and are found only in indivual’s
cancer cells. However, 1–2% of all cancers are associated with inherited cancer-
predisposition syndromes, arising in individuals who carry an inherited germline mutation of
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a cancer-susceptibility gene in every cell of their body (Fearon, 1997; Ponder, 2001). The
lifetime risk of cancer for these individuals is high (up to 50–80%), but the likelihood of
developing cancer depends on the particular mutant allele, on other genetic and non-genetic
factors (risk modifiers), and on the complex interplay of all these factors, which remains
poorly understood (Fearon, 1997; Ponder, 2001). In most inherited cancer-predisposition
syndromes, inheritance follows an autosomal dominant mode and cancer susceptibility is due
to inactivating loss-of-function mutations in gatekeeper and caretaker TSGs, rather than
activating gain-of-function alterations in proto-oncogenes (Fearon, 1997; Kinzler and
Vogelstein, 1997). Inherited cancer-predisposition syndromes are characterized by multiple
affected family members, early age at cancer onset, and multiple primary cancers. Some of
the syndromes also feature other rare conditions, particularly congenital abnormalities
(Fearon, 1997). However, in some families segregating a mutant allele of a major inherited
cancer-susceptibility gene, no striking features of inherited cancer-predisposition syndromes
are seen, possibly due to small family size, uncertain family history, or incomplete
penetrance. In addition to hereditary cancers that occur in association with rare inherited
cancer-predisposition syndromes, an unknown fraction of cancers are due to cosegregation of
mutant alleles of minor cancer-susceptibility genes, conferring low to moderate cancer risk;
these mutant alleles are estimated to be relatively common in the general population, and
thus, may confer a higher population-attributable risk for cancer (Ponder, 2001).
5 Inherited predisposition to breast and ovarian carcinoma
Familial association of breast and ovarian carcinoma was first suggested in the 1970s, when
large families with an excess of both breast and ovarian carcinoma, transmitted through
several generations, were identified (Lynch et al., 1972, 1978). Large families with an excess
of only breast or ovarian cancer were also described, and they were called site-specific breast
or site-specific ovarian cancer families (Lynch et al., 1972, 1981). A significant genetic
correlation detected between breast and ovarian carcinoma provided further support for the
existence of hereditary breast-ovarian cancer (HBOC) syndrome, and predisposition to these
two cancers was suggested to be due partly to mutations in the same gene and partly to
mutations in different genes (Schildkraut et al., 1989). In segregation analyses, breast cancer
was found to follow an autosomal dominant mode of inheritance in some families (Newman
et al., 1988; Claus et al., 1991), and in 1990, the first breast cancer-susceptibility gene was
mapped by genetic linkage to chromosome 17q21 in families with multiple cases of early-
onset breast cancer (Hall et al., 1990). Soon thereafter, linkage to the same chromosomal
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region was reported in breast-ovarian cancer families (Narod et al., 1991, 1995; Easton et al.,
1993) and in families with site-specific ovarian cancer (Steichen-Gersdorf et al., 1994). The
first breast-ovarian cancer-susceptibility gene BRCA1 (breast cancer 1) was identified by
positional cloning methods in 1994 (Miki et al., 1994). During the same year the second
breast cancer-susceptibility locus, BRCA2 (breast cancer 2), was localized to chromosome
13q12–q13 by linkage studies of families with multiple cases of early-onset breast cancer that
were not linked to BRCA1 (Wooster et al., 1994). Male breast cancer was found to be present
in many BRCA2-linked families (Thorlacius et al., 1995, 1996; Gudmundsson et al., 1996;
Tavtigian et al., 1996). The BRCA2 gene was identified in 1995 by positional cloning
methods (Wooster et al., 1995), and its complete coding sequence and exonic structure were
described in 1996 (Tavtigian et al., 1996).
Approximately 10% of all ovarian carcinomas and 7% of all breast carcinomas are
estimated to be associated with dominantly inherited germline mutations in breast/ovarian
cancer-susceptibility genes (Claus et al., 1996). Moreover, a large twin study has shown that
heritable factors are of importance in about 30% of all breast cancers (Lichtenstein et al.,
2000). Germline mutations in the BRCA1 and BRCA2 genes seem to account for the majority
of families with multiple cases of both breast and ovarian cancer and of those with site-
specific ovarian cancer, but only for a small proportion of site-specific breast cancer families
(Steichen-Gersdorf et al., 1994; Ford et al., 1995, 1998; Rebbeck et al., 1996; Håkansson et
al., 1997; Schubert et al., 1997; Serova et al., 1997; Vehmanen et al., 1997a; Zelada-Hedman
et al., 1997; Boyd, 1998; Kainu et al., 2000; Eerola et al., 2001a). In addition, a number of
other rare hereditary cancer-predisposition syndromes include breast and/or ovarian
carcinoma in their clinical presentation; breast cancer has been identified as a component of
Li-Fraumeni syndrome, Cowden disease, Peutz-Jeghers syndrome, ataxia-telangiectasia, and
cutaneous malignant melanoma (Kamb et al., 1994; Arver et al., 2000; Borg et al., 2000),
while ovarian carcinoma manifests in hereditary non-polyposis colorectal cancer (HNPCC)
syndrome and in Peutz-Jeghers syndrome (Arver et al., 2000). However, these syndromes
explain only a small proportion of all hereditary breast and ovarian cancers (Arver et al.,
2000). The residual inherited susceptibility to breast cancer may be partly due to rare
mutations in one or a few additional major breast cancer-susceptibility genes conferring a
high risk of disease (high-penetrance alleles) (Serova et al., 1997; Kainu et al., 2000; Cui et
al., 2001), and evidence for both dominantly and recessively inherited risk has been presented
(Antoniou et al., 2001, 2002; Cui et al., 2001). Nevertheless, several common, low-
penetrance alleles with multiplicative effects on breast cancer risk have been proposed to be
responsible for a large fraction of hereditary breast cancers (Antoniou et al., 2001, 2002). The
possibility that additional ovarian cancer-susceptibility genes exist has been suggested as well
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(Sekine et al., 2001a). In the Finnish population, a recessive mode of inheritance of ovarian
carcinoma has been proposed (Auranen and Iselius, 1998).
6 BRCA1 and BRCA2 genes
6.1 Structure and expression
The BRCA1 gene covers 81 kilobases (kb) of genomic DNA on chromosome 17q21 and has
24 exons, 22 of which are encoding (Miki et al., 1994; Smith et al., 1996). The BRCA2 gene
is distributed over roughly 70 kb of genomic DNA on chromosome 13q12, and of its 27
exons, 26 are encoding (Wooster et al., 1995; Tavtigian et al., 1996). Both genes have a large
exon 11 (comprising 61% and 48% of the whole coding sequences of BRCA1 and BRCA2,
respectively) and have translational start sites in exon 2 (Miki et al., 1994; Tavtigian et al.,
1996). In BRCA1, exon 4 is not translated (Miki et al., 1994; Smith et al., 1996). The
genomic regions of BRCA1 and BRCA2 have unusually high (47%) densities of repetitive
DNA elements (Smith et al., 1996; Welcsh and King, 2001).
The human BRCA1 and BRCA2 genes are expressed in a wide variety of tissues, with
the highest levels of messenger ribonucleic acid (mRNA) expression seen in the testis,
thymus, and breast (Miki et al., 1994; Tavtigian et al., 1996). Studies on mice have shown
that Brca1 and Brca2 mRNA levels are highest in rapidly proliferating cell types, particularly
those undergoing differentiation (Marquis et al., 1995; Rajan et al., 1997), and their
expression levels vary during the cell cycle, peaking at the G1/S boundary (Rajan et al.,
1996). In the mouse mammary gland, expression of Brca1 and Brca2 mRNA is induced
during puberty and pregnancy, when oestrogen levels are dramatically increased, and
following treatment of ovariectomized animals with 17β-oestradiol and progesterone
(Marquis et al., 1995; Rajan et al., 1997). In human breast cancer cell lines, BRCA1 and
BRCA2 mRNA levels are also co-ordinately elevated in response to oestrogen (Spillman and
Bowcock, 1996; Marks et al., 1997).
6.2 BRCA1 and BRCA2 gene-encoded protein products and their proposed functions
The 7.8 kb BRCA1 mRNA encodes a protein with 1863 amino acids and a predicted
molecular weight of 208 kiloDaltons (kDa) (Miki et al., 1994). The BRCA2 transcript is 12
kb long and encodes a protein with 3418 amino acids and a predicted molecular weight of
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384 kDa (Tavtigian et al., 1996). Shorter, alternatively spliced isoforms have been identified
as well (Miki et al., 1994; Lu et al., 1996; Wilson et al., 1997; Zou et al., 1999).
The BRCA1 and BRCA2 proteins bear little resemblance to one another or to other
known proteins (Venkitaraman, 2002). Nevertheless, there are striking similarities in their
expression patterns, and they both appear to be involved in the process of proliferation and
differentiation in multiple tissues, notably in the mammary gland in response to ovarian
hormones (Marquis et al., 1995; Rajan et al., 1996, 1997; Spillman and Bowcock, 1996;
Marks et al., 1997). Several functional domains and structural motifs have been identified in
BRCA1 and BRCA2, and they have been found to interact with each other and with various
other proteins, including transcription factors and proteins involved in DNA double-strand
break repair (Zheng et al., 2000; Welcsh and King, 2001; Venkitaraman, 2002). Their
localization varies according to the phase of the cell cycle; during S phase, they are localized
to discrete, subnuclear foci, and after DNA damage, they rapidly relocalize to sites of DNA
synthesis (Scully et al., 1997; Chen et al., 1998; Yarden et al., 2002). BRCA1 appears to be
activated during late G1 and S phases and following DNA damage, when it has been shown to
undergo hyperphosporylation (Thomas et al., 1997).
Cells deficient in BRCA1/Brca1 or BRCA2/Brca2 accumulate chromosomal
abnormalities (Tirkkonen et al., 1997; Abbott et al., 1998; Lee et al., 1999; Xu et al., 1999;
Moynahan et al., 2001) and are hypersensitive to genotoxic agents (Sharan et al., 1997;
Gowen et al., 1998; Scully et al., 1999; Moynahan et al., 2001). This suggests that BRCA1
and BRCA2 may function as caretakers whose loss leads to genetic instability and increases
the probability that inactivation of gatekeeper TSGs and activation of proto-oncogenes will
occur, eventually leading to tumour formation (Kinzler and Vogelstein, 1997). Inactivation of
the TP53 tumour suppressor gene or other genes critical in cell-cycle checkpoint control have
been found to be frequent in tumours of Brca1/Brca2-deficient mice (Lee et al., 1999; Xu et
al., 1999). In human BRCA1 mutation-associated breast and ovarian carcinomas, inactivation
of TP53 has been suggested to be more common than in corresponding sporadic tumours
(Crook et al., 1998; Ramus et al., 1999; Buller et al., 2001; Greenblatt et al., 2001).
Furthermore, BRCA1 and BRCA2 have been shown to suppress proliferation of breast and
ovarian cancer cell lines, suggesting that they act directly to suppress tumour growth, hence
possessing gatekeeper tumour suppressor functions as well (Thompson et al., 1995; Holt et
al., 1996; Somasundaram et al., 1997; Randrianarison et al., 2001; Wang et al., 2002).
Although the precise functions of BRCA1 and BRCA2 remain unclear, there is strong
evidence that they are involved in the DNA damage response pathway, and they have been
proposed to play roles in transcriptional regulation, cell-cycle checkpoint control, DNA
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damage repair, and recombination (Zheng et al., 2000; Welcsh and King, 2001;
Venkitaraman, 2002).
The tissue-specificity of BRCA1/BRCA2 mutation-associated carcinogenesis has been
proposed to be related to their oestrogen responsiveness (Hilakivi-Clarke, 2000; Welcsh and
King, 2001). Oestrogens induce cell proliferation and stimulate development of tissues
involved in reproduction. However, they may also predispose cells to DNA damage during
periods of rapid cellular proliferation. Furthermore, oestrogens have been reported to be able
to induce direct and indirect free radical-mediated DNA damage (Cavalieri et al., 2000;
Liehr, 2000). BRCA1 and BRCA2 have been suggested to function in protecting breasts and
ovaries from genetic instability during oestrogen-induced periods of rapid cellular
proliferation (Fan et al., 1999; Hilakivi-Clarke, 2000).
6.3 Inherited germline mutations
6.3.1 Spectrum
Since the identification of the BRCA1 and BRCA2 genes (Miki et al., 1994; Wooster et al.,
1995; Tavtigian et al., 1996), more than 1000 distinct sequence variants have been described
in each gene (the BIC database). Alterations are distributed throughout the coding regions,
and disease-associated mutations are mainly frameshift, nonsense, or splice site mutations
leading to formation of truncated protein products (Ellisen and Haber, 1998; the BIC
database). Missense variants have been identified as well, but their effect on carcinogenesis is
not as easy to determine as in the case of protein-truncating mutations, which are considered
to be functionally deleterious (Shattuck-Eidens et al., 1997; Spain et al., 1999). However, in
BRCA2 exon 27, four sequence variants that result in a stop codon have been proposed to be
non-disease-associated (Mazoyer et al., 1996; Wagner et al., 1999; the BIC database).
Significance of some common missense variants has been studied by comparing the
frequencies of the variants in large series of breast/ovarian cancer cases and matched
controls, and most of them do not appear to confer an increased risk of breast or ovarian
cancer (Durocher et al., 1996; Dunning et al., 1997; Healey et al., 2000; Deffenbaugh et al.,
2002). In families with rare missense alterations, cosegregation of the variants with breast and
ovarian cancer has been used to evaluate their significance on carcinogenesis, but many
families do not have appropriate pedigree structure or sufficient samples for such an analysis
(Shattuck-Eidens et al., 1997; Vallon-Christersson et al., 2001; Fackenthal et al., 2002).
Some missense variants have been proposed to have an effect on protein function based on
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their location within functional domains or evolutionally conserved regions of the proteins
(Castilla et al., 1994; Wu et al., 1996; Stoppa-Lyonnet et al., 1997; Roth et al., 1998; Janezic
et al., 1999; Wagner et al., 1999; Brzovic et al., 2001; Smith et al., 2001). Recently,
functional studies of BRCA1 have given further support for the hypothesis that missense
alterations located within functional domains may play a role in disease predisposition
(Scully et al., 1999; Vallon-Christersson et al., 2001). Only a small number of missense
variants in either gene have been described as deleterious mutations (Górski et al., 2000;
Sekine et al., 2001a; Vallon-Christersson et al., 2001; de La Hoya et al., 2002; Meindl and
German Consortium for Hereditary Breast and Ovarian Cancer, 2002; the BIC database), and
the clinical significance of a number of amino acid substitutions in BRCA1 and BRCA2
remains still to be resolved (the BIC database).
The observed mutation spectrum is surely influenced by techniques used in mutation
screening. Most studies searching for germline mutations of BRCA1 and BRCA2 have
analysed the coding regions and splice sites of the genes, and used techniques based on
polymerase chain reaction (PCR), e.g., direct sequencing, single-strand conformation
polymorphism (SSCP) analysis, conformation-sensitive gel electrophoresis (CSGE),
denaturing gradient gel electrophoresis (DGGE), heteroduplex analysis (HA), and protein
truncation test (PTT) (the BIC database). However, by standard screening methods, only 63%
of breast cancer families showing linkage to BRCA1 in a large BCLC study could be
identified as mutation-positive (Ford et al., 1998). Large genomic rearrangements and
regulatory mutations are not detected by standard approaches and may thus account for a
proportion of cases without identified mutations. Recently, several studies have examined the
presence of large genomic rearrangements of BRCA1 and BRCA2 in breast/ovarian cancer
families; within BRCA1 and its regulatory regions, several germline rearrangements (ranging
from 0.5 to 23.8 kb) have been described (Petrij-Bosch et al., 1997; Puget et al., 1997, 1999;
Swensen et al., 1997; Rohlfs et al., 2000; Unger et al., 2000), while in BRCA2, only two such
alterations have been identified (Miki et al., 1996; Nordling et al., 1998). Many of these
rearrangements are likely to be due to Alu-mediated homologous recombination, and they
have been presumed to be less frequent in BRCA2 than in BRCA1 because of the lower
density of Alu sequences in the BRCA2 gene (20% versus 42%, respectively) (Smith et al.,
1996; Welcsh and King, 2001). Moreover, it has recently been proposed that some missense
and silent BRCA1/BRCA2 variants may lead to exon skipping and deleterious protein-
truncating mutations through disruption of critical exonic splicing enhancer sequences (Liu et
al., 2001; Fackenthal et al., 2002).
22
6.3.2 Ethnic differences in mutation spectra
Although the majority of germline alterations identified in BRCA1 and BRCA2 (57% and
63%, respectively) are unique (the BIC database), several recurrent mutations have been
described in a number of ethnic groups and populations (the BIC database), e.g., in
Ashkenazi Jews (Roa et al., 1996; Struewing et al., 1997; Fodor et al., 1998), French
Canadians (Simard et al., 1994; Tonin et al., 1998), Icelanders (Johannesdottir et al., 1996;
Thorlacius et al., 1997), Finns (Vehmanen et al., 1997a; Huusko et al., 1998), Swedes
(Håkansson et al., 1997; Bergman et al., 2001), the Dutch (Peelen et al., 1997; Petrij-Bosch et
al., 1997; Verhoog et al., 2001), Belgians (Peelen et al., 1997; Goelen et al., 1999), Russians
(Gayther et al., 1997a), Polish (Górski et al., 2000), and Hungarians (Ramus et al., 1997; van
der Looij et al., 2000). Some of the recurrent BRCA1/BRCA2 mutations are population-
specific, while others are found in a number of different populations and ethnic groups
(Neuhausen et al., 1996, 1998, 1999; Szabo and King, 1997; the BIC database). The
proportion of recurrent mutations to unique mutations varies in different populations and
subpopulations, reflecting historical influences of migration, population structure, and
geographical and cultural isolation (Szabo and King, 1997). Studies on mutation-associated
haplotype sharing between families carrying the same BRCA1/BRCA2 mutation have been
carried out to determine whether recurrent mutations are identical by descent, i.e., founder
mutations, or whether they represent distinct mutational events (Simard et al., 1994;
Friedman et al., 1995; Berman et al., 1996; Neuhausen et al., 1996, 1998; Petrij-Bosch et al.,
1997; Rohlfs et al., 2000; Bergman et al., 2001; Ikeda et al., 2001; Meindl and German
Consortium for Hereditary Breast and Ovarian Cancer, 2002).
Among Icelanders, only one mutation has been identified in each of the BRCA1 and
BRCA2 genes; the mutation located in BRCA2 accounts for the majority (76%) of Icelandic
breast cancer families with multiple affected persons (Thorlacius et al., 1997), while the
mutation located in BRCA1 has been observed in only two families (Bergthorsson et al.,
1998). In the Polish population, six distinct BRCA1 mutations and one BRCA2 mutation have
been described, and three recurrent BRCA1 mutations account for most (83%)
BRCA1/BRCA2 mutation-positive families (Górski et al., 2000). In the western part of
Sweden, one BRCA1 mutation have been reported to account for as much as 77% of
identified BRCA1/BRCA2 mutations (Bergman et al., 2001). In Finland, around 30 different
BRCA1/BRCA2 mutations have been described (Vehmanen et al., 1997a, 1997b; Huusko et
al., 1998; Syrjäkoski et al., 2000; Vahteristo et al., 2001; unpublished data), and six BRCA1
mutations and five BRCA2 mutations account for most (84%) BRCA1/BRCA2 mutations
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identified in the screening of the entire coding sequences of the genes (Vehmanen et al.,
1997a, 1997b; Huusko et al., 1998).
6.3.3 Prevalence
In outbred populations, the prevalence of BRCA1 and BRCA2 mutation carriers has been
estimated to be 0.048–0.29% (1/2083–1/345) and 0.082%–0.34% (1/1220–1/291),
respectively (Ford et al., 1995; Whittemore et al., 1997; Peto et al., 1999; Antoniou et al.,
2000, 2001, 2002). In populations with strong BRCA1/BRCA2 founder effects, mutant alleles
have been detected with higher carrier frequencies; among Ashkenazi Jews, approximately
2.5% (1/40) of individuals carry one of the three common BRCA1/BRCA2 founder mutations
(185delAG or 5382insC in BRCA1, or 6174delT in BRCA2) (Roa et al., 1996; Struewing et
al., 1997; Fodor et al., 1998), and in the Icelandic population, 0.4–0.6% (1/250–1/167) of
individuals carry one BRCA2 founder mutation [999delTCAAA (999del5)] (Johannesdottir et
al., 1996; Tavtigian et al., 1996; Thorlacius et al., 1997).
Based on early linkage analyses, BRCA1 and BRCA2 germline mutations were
estimated together to account for the large majority of families with multiple cases of breast
and/or ovarian cancer; of breast-ovarian cancer families, 80–100% were proposed to be
linked to BRCA1 (Easton et al., 1993; Narod et al., 1995), while of site-specific breast cancer
families about 45% were estimated to be linked to BRCA1 and about 35% to BRCA2 (Easton
et al., 1993; Wooster et al., 1994). Most families with ovarian cancer only were suggested to
be linked to BRCA1 (Steichen-Gersdorf et al., 1994). Later, the contribution of both BRCA1
and BRCA2 to hereditary breast cancer was evaluated in the large collaborative BCLC study
(Ford et al., 1998). The families included in this study contained at least four cases of either
female breast cancer diagnosed before the age of 60 years or male breast cancer diagnosed at
any age (ovarian cancer was not used as a selection criterion), and breast cancer was
estimated to be associated with BRCA1 and BRCA2 mutant alleles in 52% and 32% of the
families, respectively (Ford et al., 1998). Nevertheless, when the families were divided into
subgroups according to additional criteria, such as the presence of both breast and ovarian
cancer in a family, the proportions of families linked to BRCA1 or BRCA2 differed strikingly
in various subgroups. Most (81%) breast-ovarian cancer families were due to BRCA1, while
the majority (76%) of families with both male and female breast cancer were estimated to be
due to BRCA2. In families with four or five cases of female breast cancer and no cases of
ovarian cancer, only a minority was linked to BRCA1 or BRCA2 (28% and 5%, respectively)
(Ford et al., 1998).
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The prevalence of BRCA1 and BRCA2 germline mutations in breast and/or ovarian
cancer families has been examined in a number of different populations and ethnic groups
(Table 1). These studies are, however, hard to compare as definitions of family history as well
as mutation screening methods used have been highly variable. Nevertheless, germline
mutations of BRCA1/BRCA2 have been detected in most populations in 20–50% of breast
and/or ovarian cancer families (Table 1), implying that the contribution of BRCA1/BRCA2
germline mutations to hereditary breast and/or ovarian cancer predisposition is not as high as
originally estimated based on linkage analyses of extended high-risk families.
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Table 1. Prevalence of BRCA1 and BRCA2 germline mutations in series of breast and/or ovarian
cancer families.
Mutation frequency (%)Reference Population Selection criteria No. of
patients
Type of mutation
screening BRCA1 BRCA2 BRCA1/2
Vahteristo
et al., 2001
Finnish >3 bc or oc (in 1st/2nd-degree
relatives)
148 W, BRCA1 and
BRCA2 (n=95);
F, 11 in BRCA1 and
8 in BRCA2 (n=53)
10.8 8.8 19.6
Ligtenberg
et al., 1999
Dutch >3 bc or oc (in 1st/2nd/3rd-
degree relatives)
104 W, BRCA1 and
BRCA2
25.0 4.8 29.8
Thorlacius
et al., 1996
Icelandic >3 bc (in 1st-degree relatives
or in >3 generations), or >1
male bc
21 F, 1 in BRCA2 76.2
Håkansson
et al., 1997
Swedish
/Danish
>3 bc (in 1st-degree
relatives), with >1 diagnosed
at age <50 y, or 2 bc (in 1st-
degree relatives), with >1
diagnosed at age <40 y, or
>1 bc diagnosed at age <30 y
106 W, BRCA1
and BRCA2
22.6 11.3 34.0
de La Hoya
et al., 2002
Spanish >3 bc or oc (in 1st/2nd-degree
relatives), with >1 diagnosed
at age <50 y
102 W, BRCA1
and BRCA2
18.6 12.7 31.4
Tonin et al.,
1998
French
Canadian
>3 female/male bc (females
diagnosed at age <65 y) or
oc, with >2 cases in
1st/2nd/3rd-degree relatives of
the index case
97 F, 4 in BRCA1
and 4 in BRCA2
24.7 17.5 42.3
Frank et al.,
1998
American >2 bc or oc (in 1st/2nd-degree
relatives), with >1 bc
diagnosed at age <50 y
238 W, BRCA1
and BRCA2
26.5 13.0 39.5
Ikeda et al.,
2001
Japanese >2 bc (in 1st-degree
relatives), no ovarian cancer
101 W, BRCA1
and BRCA2
7.9 20.8 28.7
Meindl and
German
Consortium
for HBOC,
2002
German >2 bc, with >2 diagnosed at
age <50 y, no ovarian cancer
328 W, BRCA1
and BRCA2
24.4 12.5 36.9
Meindl and
German
Consortium
for HBOC,
2002
German >1 bc and >1 oc 250 W, BRCA1
and BRCA2
42.4 9.6 52.0
Martin et
al., 2001
American >1 bc and >1 oc 100 W, BRCA1
and BRCA2
45.0 11.0 56.0
Gayther et
al., 1997a
Russian >2 oc (in 1st-degree relatives) 19 W, BRCA1 73.7
Gayther et
al., 1999
British >2 oc (in 1st/2nd-degree
relatives)
112 W, BRCA1
and BRCA2
35.7 7.1 42.9
Gayther et
al., 1999
British 2 oc (in 1st/2nd-degree
relatives), no breast cancer
50 W, BRCA1
and BRCA2
16.0 4.0 20.0
Sekine et
al., 2001b
Japanese >2 oc (in 1st/2nd-degree
relatives), no breast cancer
55 W, BRCA1
and BRCA2
40.0 3.6 43.6
Moslehi et
al., 2000
Ashkenazi
Jewish
(Israel and
N. America)
>2 oc (in 1st/2nd-degree
relatives), no breast cancer
30 P, BRCA1 (ex 2, 11,
20) and BRCA2 (ex
10, 11)
30.0 30.0 60.0
bc, breast carcinoma; ex, exon; F, founder mutation(s); HBOC, Hereditary Breast and Ovarian Cancer; N., north; oc, ovarian
carcinoma; P, partial coding sequence; W, whole coding sequence; y, years
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In Finland, BRCA1 and BRCA2 germline mutations have been detected in 11% and 9%
of families with three or more cases of breast or ovarian cancer in first- or second-degree
relatives (Vehmanen et al., 1997a, 1997b; Vahteristo et al., 2001). The highest (80%)
frequency of mutations has been observed in families with both ovarian cancer and early-
onset (<40 years) breast cancer, while in families with later onset (>40 years) breast cancer
only, the mutation frequency has been lowest (1.5%) (Table 2) (Vahteristo et al., 2001).
Table 2. Frequency of BRCA1/BRCA2 germline mutations in Finnish breast and
breast-ovarian cancer families according to family history of breast and/or ovarian
cancer (modified from Vahteristo et al., 2001).
Criteriaa No. of families Mutation frequency (%)
3 affected 74 10.8
Only breast cancer, none under 40 y 47 2.1
Only breast cancer, some under 40 y 15 6.7
Breast and ovarian cancer, none under 40 y 9 33.3
Breast and ovarian cancer, some under 40 y 3 100
4 affected 35 22.9
Only breast cancer, none under 40 y 15 0
Only breast cancer, some under 40 y 7 14.3
Breast and ovarian cancer, none under 40 y 11 36.4
Breast and ovarian cancer, some under 40 y 3 100
> 5 affected 39 33.3
Only breast cancer, none under 40 y 6 0
Only breast cancer, some under 40 y 10 20.0
Breast and ovarian cancer, none under 40 y 9 11.1
Breast and ovarian cancer, some under 40 y 14 71.4
Total 148 19.6
Only breast cancer, none under 40 y 68 1.5
Only breast cancer, some under 40 y 32 12.5
Breast and ovarian cancer, none under 40 y 28 28.6
Breast and ovarian cancer, some under 40 y 20 80.0
y, years; aIn first- or second-degree relatives
Studies on population- and hospital-based series of female breast cancer patients
unselected for family history of cancer have reported BRCA1 and BRCA2 germline mutations
in 0.4–16.5% and 0.2–24.0% of patients, respectively (Johannesdottir et al., 1996; Krainer et
al., 1997; Thorlacius et al., 1997; Fodor et al., 1998; Malone et al., 1998; Hopper et al., 1999;
Peto et al., 1999; Tang et al., 1999; Warner et al., 1999; ABCSG, 2000; Anton-Culver et al.,
2000; Syrjäkoski et al., 2000; van der Looij et al., 2000; Loman et al., 2001; Tonin et al.,
2001; Liede et al., 2002). The highest BRCA1 mutation frequencies have been reported
among Ashkenazi Jewish (16.5%) and Icelandic (15.8%) breast cancer patients diagnosed
before the age of 50 years (Warner et al., 1999), while the highest BRCA2 mutation frequency
(24.0%) has been described in Icelandic breast cancer patients diagnosed before the age of 40
years (Thorlacius et al., 1997). In general, BRCA1/BRCA2 mutation frequencies are higher
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among cases diagnosed at an earlier age. Among Ahkenazi Jews and Icelanders,
BRCA1/BRCA2 mutations have been detected in 7–12% (Fodor et al., 1998; Warner et al.,
1999) and 8–9% (Johannesdottir et al., 1996; Thorlacius et al., 1997), respectively, of breast
carcinomas unselected for age at diagnosis and family history of cancer. In 1035 unselected
Finnish breast cancer patients, the combined frequency of BRCA1 and BRCA2 mutations was
14.3%, 9.8%, 5.0%, 3.1%, 2.3%, and 2.0% among patients diagnosed at the age of <35 years,
<40 years, <45 years, <50 years, <55 years, and <75 years, respectively (Syrjäkoski et al.,
2000; some of the data is unpublished). Overall, the frequency of BRCA2 mutations (1.4%)
was notably higher than that of BRCA1 mutations (0.4%) in unselected Finnish breast cancer
patients (Syrjäkoski et al., 2000).
In unselected ovarian carcinoma patients, the frequency of BRCA1 and BRCA2
mutations has been reported to be 0–27.4% and 0–13.9%, respectively (Table 3). The highest
proportion of unselected ovarian cancer patients carrying BRCA1/BRCA2 mutations has been
reported among Ashkenazi Jews (25–41%) (Moslehi et al., 2000; Tobias et al., 2000). In
admixed American, Canadian, and British populations, BRCA1 and BRCA2 mutations have
been reported in unselected ovarian carcinoma patients with frequencies varying from 2% to
9% (Stratton et al., 1997; Rubin et al., 1998; Janezic et al., 1999; Anton-Culver et al., 2000;
Risch et al., 2001; Smith et al., 2001) and 1% to 4% (Takahashi et al., 1996; Rubin et al.,
1998; Risch et al., 2001), respectively. Early-onset ovarian carcinoma does not seem to be
related to BRCA1/BRCA2 mutations, as no mutations were detected in a study of patients
diagnosed below the age of 30 years (Stratton et al., 1999).
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Table 3. Prevalence of BRCA1 and BRCA2 germline mutations in population- and hospital-based
series of ovarian carcinoma patients unselected for family history of cancer.
Reference Population Type of sample Age, y Mutation frequency (%)No. of
patients
Type of mutation
screening BRCA1 BRCA2 BRCA1/2
Stratton et
al., 1999
British Population-based <30 101 W, BRCA1;
P, BRCA2 (OCCR)
0 0 0
Stratton et
al., 1997
British Hospital-based <70 374 W, BRCA1 3.5
Smith et al.,
2001
American
(throughout)
Hospital-based 20–74 258 W, BRCA1 4.7
Takahashi et
al., 1996
American
(PA and
tissue bank)
Hospital-based All
ages
130 W, BRCA2 3.1
Anton-Culver
et al., 2000
American
(CA)
Population-based All
ages
120 W, BRCA1
(n=107);
F, 7 in BRCA1
(n=13)
3.3
Janezic et al.,
1999
American
(CA)
Population-based All
ages
107 W, BRCA1 1.9
Rubin et al.,
1998
American
(PA)
Hospital-based All
ages
116 W, BRCA1
and BRCA2
8.6 0.9 9.5
Berchuck et
al., 1998
American
(NC)
Hospital-based All
ages
103 W, BRCA1 3.9
Risch et al.,
2001
Canadian
(Ontario)
Population-based All
ages
515 P, BRCA1 (ex11)
and BRCA2 (ex 10,
11);
F, 7 in BRCA1
and 4 in BRCA2
7.6 4.1 11.7
Tonin et al.,
1999
French
Canadian
Hospital-based All
ages
99 F, 3 in BRCA1 and
4 in BRCA2
5.1 3.0 8.1
Johannesdottir
et al., 1996
Icelandic Hospital-based All
ages
38 F, 1 in BRCA2 7.9
van der Looij
et al., 2000
Hungarian Hospital-based All
ages
90 F, 3 in BRCA1
and 2 in BRCA2
11.1 0
Khoo et al.,
2000
Chinese Hospital-based All
ages
53 for
BRCA1
and 48
for
BRCA2
W, BRCA1;
P, BRCA2 (ex 11)
11.3 2.1
Liede et al.,
2002
Pakistani Hospital-based All
ages
120 P, BRCA1 (ex 2,
11, 12, 15, 20) and
BRCA2 (ex 10, 11,
22)
13.3 2.5 15.8
Tobias et
al., 2000
Ashkenazi
Jewish
(USA)
Hospital-based All
ages
92 F, 2 in BRCA1
and 1in BRCA2
17.4 7.6 25.0
Moslehi et
al., 2000
Ashkenazi
Jewish
(Israel and N.
America)
Hospital-based All
ages
208 P, BRCA1 (ex 2,
11, 20) and BRCA2
(ex 10, 11)
27.4 13.9 41.3
CA, California; ex, exon; F, founder mutation(s); N., north; NC, North Carolina; OCCR, ovarian cancer cluster region; P, partial
coding sequence; PA, Pennsylvania; W, whole coding sequence
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6.4 Risk of cancer in BRCA1 and BRCA2 mutation carriers
The initial risk estimates, based on the large, original breast and breast-ovarian cancer
families collected for BRCA1/BRCA2 linkage analyses, were generally very high. For BRCA1
mutation carriers, the cumulative risk of female breast and ovarian cancer by the age of 70
years was estimated to be 71–87% and 42–63%, respectively (Ford et al., 1994; Easton et al.,
1995; Narod et al., 1995). For BRCA2 mutation carriers, the cumulative risk of female breast
cancer by the age of 70 years was estimated to be similar (67–84%) to that of BRCA1
mutation carriers, but the risk of ovarian cancer was estimated to be substantially lower (16–
27% by the age of 70 years) (Schubert et al., 1997; Ford et al., 1998; the BCLC, 1999). The
risk of subsequent breast and ovarian cancer has also been reported to be very high in breast
cancer patients with BRCA1 or BRCA2 mutations; 52–64% of BRCA1/BRCA2 mutation
carriers were affected with contralateral breast cancer by the age of 70 years, and 29–44% of
BRCA1 mutation carriers and 8–16% of BRCA2 mutation carriers developed subsequent
ovarian cancer by the same age (Ford et al., 1994; the BCLC, 1999; Eerola et al., 2001a). The
cumulative risk of male breast cancer by the age of 70 years has been estimated to be 3–6%
for BRCA2 mutation carriers (Easton et al., 1997; Thompson and Easton, 2001).
Studies based on population- and hospital-based series of breast/ovarian cancer patients
and unaffected individuals have reported considerably lower breast and ovarian cancer risk
estimates for BRCA1 and BRCA2 mutation carriers than studies consisting of families with
multiple cases of breast and/or ovarian cancer. In the Icelandic population, the cumulative
risk of female breast cancer for BRCA2 999del5 mutation carriers has been estimated to be
37% by the age of 70 years (Thorlacius et al., 1998). Among Ashkenazi Jews, the risk of
breast cancer by the same age has been reported to be 46–60% for BRCA1 mutation carriers
(185delAG or 5382insC) and 26–28% for carriers of the BRCA2 6174delT founder mutation
(Warner et al., 1999; Satagopan et al., 2001); the risk of ovarian cancer has been estimated to
be 16% for those who carry any of the three Ashkenazi Jewish founder mutations (Struewing
et al., 1997). Also in admixed British and Australian populations, where BRCA1/BRCA2
mutation spectra are wider, lower risk estimates have been observed (Hopper et al., 1999;
Peto et al., 1999; ABCSG, 2000; Antoniou et al., 2000, 2002); the cumulative risk of breast
cancer by the age of 70 years has been estimated to be 35–47% for BRCA1 mutation carriers
and 50–56% for BRCA2 mutation carriers. Estimates of ovarian carcinoma risk by the age of
70 years have varied between 26% and 66% for BRCA1 mutation carriers, while for BRCA2
mutation carriers, substantially lower ovarian carcinoma risk estimates (9–10% by the age of
70 years) have been reported (ABCSG, 2000; Antoniou et al., 2000, 2002).
30
In addition, several studies have suggested that the risk of prostate cancer is increased
in both BRCA1 (Arason et al., 1993; Ford et al., 1994; Struewing et al., 1997; Warner et al.,
1999) and BRCA2 mutation-associated families (Struewing et al., 1997; Thorlacius et al.,
1997; the BCLC, 1999; Johannsson et al., 1999; Warner et al., 1999; Eerola et al., 2001a).
Nevertheless, BRCA1/BRCA2 germline mutations appear to have a minor role in familial
prostate cancer (Langston et al., 1996; Sinclair et al., 2000).
The risk of cancer may vary according to the location of the mutation in BRCA1 and
BRCA2 (Gayther et al., 1995, 1997b; Risch et al., 2001; Thompson and Easton, 2001, 2002).
In BRCA1, mutations located in the first two-thirds of the coding sequence have been
suggested to be associated with a higher ovarian cancer risk relative to breast cancer risk than
mutations in the last third of the gene [optimal breakpoint between nucleotides (nt) 4422 and
4448 (Gayther et al., 1995), or at nt 4191 (Thompson and Easton, 2002)]. However, others
have observed no difference in ovarian cancer risk according to the location of the mutation,
while the risk of breast cancer has been found to increase towards the 3´ end of the gene
(Risch et al., 2001). Moreover, the breast cancer risk associated with mutations in the central
region of the BRCA1 gene (nt 2401–4190) has been reported to be lower than in mutations in
the outer two regions (Thompson and Easton, 2002). In BRCA2, mutations located in the
central portion of the gene, in an area termed the ovarian cancer cluster region (OCCR)
[optimal location either between nt 3035 and 6629 (Gayther et al., 1997b), or between nt
3059 and 4075, and 6503 and 6629 (Thompson and Easton, 2001)], have been reported to be
associated with a higher ratio of ovarian to breast cancer cases than mutations located outside
the region (Gayther et al., 1997b; Thompson and Easton, 2001). The distinctive phenotype
associated with mutations located in the OCCR relative to other BRCA2 mutations has been
suggested to be predominantly due to a reduced risk of breast cancer rather than an increased
risk of ovarian cancer (Thompson and Easton, 2001). Furthermore, the risk of prostate cancer
has been suggested to be higher for non-OCCR mutations than for mutations located within
the OCCR (34% and 19%, respectively, by the age of 80 years) (Thompson and Easton,
2001).
Evidence exists for a modifying effect of other genes as well as non-genetic factors on
the risks of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers (Hopper et al.,
1999; Antoniou et al., 2000, 2002; Nathanson and Weber, 2001), which may explain some of
the differences in risk estimates obtained from studies based on population- and hospital-
based series of breast and ovarian cancer patients and those based on families selected on the
basis of multiple occurrence of breast/ovarian carcinoma. Several association studies have
reported that allelic variation in genes involved in steroid hormone signalling pathways (e.g.,
androgen receptor and progesterone receptor genes) may affect cancer penetrance in BRCA1
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and BRCA2 mutation carriers (Rebbeck et al., 1999a, 2001; Runnebaum et al., 2001). Non-
genetic factors that may influence breast/ovarian cancer risk of BRCA1 and/or BRCA2
mutation carriers include pregnancy (Johannsson et al., 1998; Jernström et al., 1999; Modan
et al., 2001), smoking (Brunet et al., 1998), bilateral prophylactic oophorectomy (Rebbeck et
al., 1999b, 2002) and mastectomy (Hartmann et al., 1999), and use of tamoxifen (an anti-
oestrogenic drug) (Narod et al., 2000; King et al., 2001; Duffy and Nixon, 2002).
6.5 Prediction of presence of a BRCA1/BRCA2 germline mutation in a family
As screening of BRCA1 and BRCA2 mutations is laborious and expensive, and genetic
mutation testing is emotionally stressful for families, it is important to find clinical risk
factors that could best predict the presence of a BRCA1/BRCA2 mutation in a family so that
mutation screening could be directed to potential mutation carrier families. According to the
guidelines of the American Society of Clinical Oncology (1996) and the French National Ad
Hoc Committee (Eisinger et al., 1998), the chance of detecting a mutation should be above
10% and 25%, respectively. Many studies have been performed to develop models to
estimate the likelihood that a woman carries a BRCA1/BRCA2 germline mutation based on
her personal and family history of breast and ovarian cancer (Berry et al., 1997; Couch et al.,
1997; Shattuck-Eidens et al., 1997; Frank et al., 1998; Malone et al., 1998; Parmigiani et al.,
1998; Hodgson et al., 1999; Ligtenberg et al., 1999; Ikeda et al., 2001; Loman et al., 2001;
Vahteristo et al., 2001; de La Hoya et al., 2002). In general, the stronger the family history of
breast and/or ovarian cancer and the younger the age at breast cancer diagnosis, the more
likely the family is to carry a BRCA1 or BRCA2 mutation. However, most women with a
family history of breast and/or ovarian cancer are not members of large families with multiple
cases of breast and ovarian cancer but instead have only a few affected family members
(Couch et al., 1997; Goelen et al., 1999; Ligtenberg et al., 1999; Ikeda et al., 2001).
Nevertheless, also in these cases, the presence of ovarian cancer in a family, bilateral breast
cancer, the presence of both breast and ovarian cancer in the same woman, and the age at
diagnosis of the youngest breast cancer patient are useful in predicting the presence of a
BRCA1/BRCA2 mutation (Berry et al., 1997; Couch et al., 1997; Frank et al., 1998; Malone et
al., 1998; Hodgson et al., 1999; Ligtenberg et al., 1999; Loman et al., 2001). Furthermore, the
histopathological phenotype of breast cancer has been suggested to be useful in predicting
BRCA1 mutation carrier status (Eisinger et al., 1999; Cortesi et al., 2000; Lidereau et al.,
2000).
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6.6 Characteristics of BRCA1 and BRCA2 mutation-associated breast and ovarian
carcinomas
6.6.1 Breast carcinomas
Evidence has been found for phenotypic differences between breast carcinomas occurring in
women carrying germline mutations in BRCA1 and BRCA2 and those occurring in non-
carriers (Phillips, 2000). Both BRCA1 and BRCA2 mutation-associated breast carcinomas are
diagnosed on average at a younger age than sporadic ones (Marcus et al., 1996; Noguchi et
al., 1999), and bilateral breast carcinoma is more common among BRCA1/BRCA2 mutation
carriers than among patients with sporadic breast carcinoma (Ford et al., 1994; Easton et al.,
1995; Verhoog et al., 1998; the BCLC, 1999; Noguchi et al., 1999). BRCA1 mutation-
associated breast carcinomas are more often highly proliferating, aneuploid, and of high
histological grade than sporadic control tumours (Marcus et al., 1996; the BCLC, 1997;
Jóhannsson et al., 1997; Lakhani et al., 1998; Armes et al., 1999; Noguchi et al., 1999).
Furthermore, BRCA1 mutation-associated breast tumours have been found to be more
frequently oestrogen receptor- (ESR) and progesterone receptor- (PGR) negative, as well as
negative for the ERBB2 oncoprotein (Jóhannsson et al., 1997; Loman et al., 1998; Verhoog et
al., 1998; Armes et al., 1999; Noguchi et al., 1999). Finally, they have been observed to have
a higher frequency of sporadic TP53 mutations and/or overexpression of the TP53 protein as
compared with sporadic control tumours (Crook et al., 1998; Armes et al., 1999; Noguchi et
al., 1999; Greenblatt et al., 2001).
For BRCA2 mutation-associated breast carcinomas, no distinct phenotype has been
documented (Armes et al., 1999; Noguchi et al., 1999; Phillips, 2000). Nevertheless,
compared with BRCA1 mutation-associated tumours, they tend to be more often ESR- and
PGR-positive (Loman et al., 1998; Armes et al., 1999; Verhoog et al., 1999, Duffy, 2002
#1650), and show no clear increase in the frequency of TP53 mutations and/or
overexpression of the TP53 protein (Armes et al., 1999; Noguchi et al., 1999; Phillips, 2000).
A comparative genomic hybridization (CGH) study has shown that the total number of
somatic genetic alterations is almost two times higher in breast tumours from both BRCA1
and BRCA2 mutation carriers than in control tumours (Tirkkonen et al., 1997). Furthermore,
BRCA1 and BRCA2 tumours have been found to be characterized by distinct CGH changes,
suggesting that specific genetic pathways may operate in the progression of these tumours
(Tirkkonen et al., 1997). Recently, using complementary DNA (cDNA) microarray
technology, Hedenfalk et al. (2001) determined global gene expression profiles in BRCA1
and BRCA2 mutation-associated breast carcinomas as well as in sporadic tumours and found
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that these three groups of tumours expressed significantly different groups of genes and could
thus be distinguished from each other.
6.6.2 Ovarian carcinomas
Both BRCA1 and BRCA2 mutation-associated ovarian carcinomas are typically of serous
histology, moderate to high grade, and advanced stage (Rubin et al., 1996; Aida et al., 1998;
Boyd et al., 2000; Moslehi et al., 2000; Werness et al., 2000; Risch et al., 2001). Compared
with sporadic carcinomas, mucinous subtype is underrepresented in BRCA1 and BRCA2
mutation carriers (Boyd et al., 2000; Moslehi et al., 2000; Werness et al., 2000; Risch et al.,
2001). Moreover, epithelial ovarian tumours of low malignant potential, i.e., borderline
ovarian tumours, do not seem to be associated with BRCA1 or BRCA2 mutations (Gotlieb et
al., 1998; Werness et al., 2000; Risch et al., 2001). In BRCA1 mutation carriers, ovarian
carcinomas are diagnosed on average at a younger age than sporadic ones, while for BRCA2
mutation-associated ovarian carcinomas, the mean age at diagnosis does not differ from that
of sporadic tumours (Boyd et al., 2000; Moslehi et al., 2000; Risch et al., 2001).
Somatic alterations of the TP53 gene and/or overexpression of the TP53 protein have
been suggested to be more common in BRCA1/BRCA2 mutation-associated ovarian
carcinomas than in sporadic tumours (Ramus et al., 1999; Buller et al., 2001). Nevertheless,
some have found no difference in TP53 expression between BRCA1/BRCA2 mutation-
positive and -negative ovarian tumours (Zweemer et al., 1999; Ravid et al., 2000). Mutations
of KRAS and amplification of ERBB2, MYC, and AKT2, which are commonly seen in
sporadic ovarian carcinoma, have not been observed in BRCA1/BRCA2 mutation-associated
ovarian carcinomas (Rhei et al., 1998; Tanner et al., 2000).
A study using CGH has reported genetic similarity between BRCA1/BRCA2 mutation-
associated and sporadic ovarian carcinomas of serous histology both in total number of
somatic genetic alterations and their location, suggesting a common main pathway in tumour
progression (Tapper et al., 1998). Recently, a cDNA microarray study of BRCA1/BRCA2
mutation-positive and -negative ovarian tumours of similar stage, grade, and histology
observed a great contrast in gene expression profiles betweeen tumours of BRCA1 mutation
carriers and those of BRCA2 mutation carriers (Jazaeri et al., 2002). Among sporadic
tumours, ”BRCA1-like” and ”BRCA2-like” subgroups were seen, suggesting that mutations in
BRCA1 and BRCA2 may lead to carcinogenesis through distinct molecular pathways that also
appear to be involved in sporadic cancers (Jazaeri et al., 2002).
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6.7 Prognosis of patients with BRCA1 or BRCA2 mutation-associated breast or ovarian
carcinoma
Most studies on survival of breast cancer patients with BRCA1 mutations (Gaffney et al.,
1998; Jóhannsson et al., 1998; Verhoog et al., 1998; Eerola et al., 2001b) or BRCA2
mutations (Gaffney et al., 1998; Verhoog et al., 1999, 2000; Eerola et al., 2001b) have
suggested that their prognosis does not differ significantly from that of sporadic cases.
For ovarian carcinoma, conflicting results have been presented, with BRCA1 or BRCA2
mutation-associated patients proposed to have better (Rubin et al., 1996; Aida et al., 1998;
Boyd et al., 2000; Ben David et al., 2002), equal, or worse prognosis (Jóhannsson et al.,
1998; Pharoah et al., 1999) than sporadic patients.
7 Population history of Finland and its influence on the Finnish gene pool
7.1 Settlement in Finland
According to the dual-origins hypothesis, Finland was inhabited by two main migratory
waves: an earlier wave of eastern Uralic speakers from about 4000 years ago was followed by
a wave about 2000 years ago from the south via the Gulf of Finland (Kittles et al., 1998;
Peltonen et al., 1999). Nevertheless, it seems more likely that Finland has been inhabited
continuously since the last glacial period around 10 000 years ago by small immigrant groups
mainly from the south and east but also from the west (Jutikkala and Pirinen, 1996; Peltonen
et al., 1999; Norio, 2000). Both Y-chromosomal haplotypes and mitochondrial sequences
show a decrease in genetic diversity of the Finns as compared with other European
populations, indicating a bottleneck in the founding of the Finnish population (Sajantila et al.,
1996).
Agriculture arrived in Finland approximately 4000 to 5000 years ago (Jutikkala and
Pirinen, 1996), and it first spread slowly into the southern and western coastal areas. The
early settlement region (Figure 1) has had permanent inhabitation for at least 2000 years,
while the settling of the central and northern parts of the country (late settlement region)
began only in the 16th century (Nevanlinna, 1972; Norio et al., 1973). The spread of the
population towards the east and north occurred partly due to a royal decree that ordered
people from the region of South Savo to settle in uninhabited areas. This resulted in repeated
sampling of small numbers of settlers from the main population (multiple founder effects)
and formation of small, rural subisolates which remained relatively stable until the Second
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World War and industrialization (Nevanlinna, 1972; Norio et al., 1973; Peltonen et al., 1999).
Since then, migration to towns has increased, but gene flow between rural communities has
remained limited (Norio et al., 1973). Wars, great famine (during 1696–1698), and epidemics
prevented continuous population growth until the 18th century, after which the population
expanded rapidly from 250 000 to its present size of about 5.1 million (Norio et al., 1973;
Peltonen et al., 1999). Due to linguistic, religious, cultural, and geographical barriers, the
main expansion of the Finnish population occurred in remarkable isolation (Nevanlinna,
1972; Norio et al., 1973). This rapid expansion of the Finnish population in a subisolate
structure allowed random genetic drift to play with allele frequencies, resulting in allele
enrichments and losses in rural subisolates (Nevanlinna, 1972; Norio et al., 1973, 2000).
Figure 1. Map of Finland indicating the early and late settlement areas. The early settlement region
has had permanent inhabitation for at least 2000 years, while the late settlement region was inhabited
only after the 16th century by internal migration movement mainly from the region of South Savo.
Adapted from Norio et al. (1973).
7.2 Finnish disease heritage
The population history of Finland is reflected in the unique disease pattern known as ”the
Finnish disease heritage”. This concept was introduced in 1973 by Drs. Norio, Nevanlinna,
and Perheentupa (Norio et al., 1973), and it refers to diseases that are more prevalent in the
Finnish population than in other populations. On the other hand, some diseases that are
common elsewhere are extremely rare in Finland. At present, more than 30 monogenic
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disorders are included in the Finnish disease heritage. Most disorders are autosomal
recessive, but two autosomal dominant, and two X-chromosomal recessive disorders have
been described (de la Chapelle and Wright, 1998; Norio, 2000; Kere, 2001). To date, all but
two of the disease loci have been mapped, and the gene and its common mutations are known
for 22 diseases (Kere, 2001). Diseases of the Finnish disease heritage are typically caused by
one major mutation originating from a common ancestor, i.e., a founder mutation, but for
some diseases, multiple founder mutations have been described (Peltonen et al., 1999; Kere,
2001). Distinct geographical clustering of affected individuals is indicative of founder effects
and is seen in many diseases of the Finnish disease heritage even today. Nevertheless, the
most common recessive disorders are fairly equally distributed throughout the country, or
their distribution closely resembles the present-day population density of Finland (Peltonen et
al., 1995, 1999; Norio, 2000). It is noteworthy that there appears to be some clustering of
these diseases, reflecting regional subisolates (Norio, 2000).
7.3 Inherited diseases other than those included in the Finnish disease heritage
Also in inherited diseases that are not overrepresented in Finland as compared with other
populations, distinct founder effects have been described (Kere, 2001). For example, in
familial hypercholesterolemia, four Finnish founder mutations in the low-density lipoprotein
receptor gene are responsible for three-quarters of the cases in Finland, and the distribution of
these mutations varies in different parts of the country (Koivisto et al., 1992, 1995). In
HNPCC, two founder mutations in the MLH1 gene account for approximately half of all
Finnish HNPCC families (Nyström-Lahti et al., 1995, 1996), and distinct geographical
clustering of the ancestral origins of families with these mutations has been observed (Moisio
et al., 1996).
7.4 Linkage disequilibrium and haplotypes
Founder mutations are characterized by linkage disequilibrium (LD), i.e., non-random
association of alleles at closely linked loci. Due to recombination, LD gradually decays as a
function of the number of generations, and the time required for disappearance of LD
between alleles depends crucially on the genetic distance between the loci (Jorde, 1995).
Around disease alleles of the Finnish disease heritage, significant LD has been detected over
large genetic distances, varying between 2 and 13 centiMorgans (cM) (Peltonen et al., 1999).
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Moreover, in HNPCC, marked LD over a genetic distance of 18 cM around a MLH1 mutant
allele has been reported in Finnish families (Moisio et al., 1996). Although LD can be
observed over wide genetic intervals, identical haplotypes (combinations of alleles) around
disease alleles in affected individuals from different families are systematically found only
across very restricted areas (Peltonen et al., 1999; Kere, 2001). For example, carriers of the
Finnish MLH1 founder mutation shared an identical haplotype of 2 cM (Moisio et al., 1996).
LD mapping and monitoring of shared haplotypes have been successfully used in fine-
mapping of disease loci in the Finnish population (Hästbacka et al., 1992, 1994; Lehesjoki et
al., 1993; Nyström-Lahti et al., 1994; Höglund et al., 1995; Schleutker et al., 1995; Peltonen
et al., 2000a). Power to detect LD tends to be greatest when a single mutant allele that
accounts for a large proportion of affected individuals has arisen recently on a relatively
uncommon haplotype background. Locus and allelic heterogeneity, which is common in
complex diseases, decreases the power to detect LD (Jorde, 2000). LD is also influenced by
numerous forces, e.g., mutation, natural selection, gene flow, demographic history,
chromosomal location, and gene conversion, which complicate the relationship between LD
and physical distance (Laan and Pääbo, 1997; Zavattari et al., 2000; Daly et al., 2001;
Pritchard and Przeworski, 2001). Finnish subpopulations have been used in the genetic
studies of multifactorial diseases, such as multiple sclerosis (Kuokkanen et al., 1997),
schizophrenia (Hovatta et al., 1999; Ekelund et al., 2000; Paunio et al., 2001), and asthma
and atopy (Laitinen et al., 2001). In most cases, these linkage-based approaches have resulted
in the initial positioning of several susceptibility loci, but no individual genes have yet been
identified based on these studies.
The extent of LD around mutation alleles can give some clues of the time elapsed since
a mutation was introduced into a population (Peltonen et al., 1995; de la Chapelle and
Wright, 1998). To estimate the age of a mutation, several statistical approaches have been
developed (Slatkin and Rannala, 2000; Rannala and Bertorelle, 2001). The equation of Luria
and Delbrück (1943), originally introduced to estimate mutation rates in rapidly growing
bacterial cultures, has been adapted to estimate genetic distances between disease loci and
linked markers in the Finnish population (Hästbacka et al., 1992, 1994; Lehesjoki et al.,
1993; Höglund et al., 1995; Schleutker et al., 1995). The same equation can be applied to
estimate the age of a mutation since its appearance in the Finnish population (Höglund et al.,
1996), the expansion of which is considered to have occurred rapidly and in remarkable
isolation (Nevanlinna, 1972; Norio et al., 1973). Distribution of birthplaces of mutation
carriers’ ancestors is also of importance in estimating the time elapsed since a mutation was
introduced into a population (Peltonen et al., 1995; Norio, 2000). The most common
disorders of the Finnish disease heritage that are more or less equally distributed throughout
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the country (e.g., aspartyl-glucosaminuria and congenital nephrosis) show significant LD
spanning only 2–3 cM, and these mutations may have been introduced into the Finnish
population thousands of years ago (Peltonen et al., 1995, 1999; Norio, 2000). In contrast,
diseases with more restricted geographical distribution show LD extending over larger
genetic distances (10–13 cM) (Peltonen et al., 1995, 1999; Norio, 2000). For instance,
mutations that cause congenital chloride diarrhoea and variant late infantile neuronal ceroid
lipofuscinosis have been estimated to have started to spread in Finnish subpopulations 13–30
generations (i.e., ca. 400–500 years) ago (Höglund et al., 1996; Varilo et al., 1996). In
HNPCC, where LD extended 18 cM around a MLH1 mutant allele and affected members of
different families shared a common haplotype of 2 cM, the spread of the mutation was
estimated to have started 16–43 generations ago (Moisio et al., 1996).
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AIMS OF THE STUDY
At the time this work began, 11 distinct germline mutations in BRCA1 and seven in BRCA2
had been identified in Finnish breast and breast-ovarian cancer families (Vehmanen et al.,
1997a, 1997b; Huusko et al., 1998). Of these 18 different BRCA1/BRCA2 mutations, 11 had
been described in more than one Finnish family. These recurrent mutations accounted for the
vast majority (84%) of all BRCA1 and BRCA2 mutations found in the screening of the entire
coding regions of the genes (Vehmanen et al., 1997a, 1997b; Huusko et al., 1998).
The aims of this thesis were to study:
1) ancestral origins and geographical distribution of families with recurrent Finnish
BRCA1/BRCA2 germline mutations (I, II)
2) breast and ovarian cancer phenotypes of Finnish BRCA1 and BRCA2 germline mutation
carriers (I)
3) the prevalence of BRCA1 and BRCA2 founder mutations in Finnish ovarian carcinoma
patients (III) and ovarian carcinoma families (IV)
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MATERIALS AND METHODS
1 Ethical issues
Appropriate research permissions were obtained from the Ministry of Social Affairs and
Health in Finland, and from the Ethics Committees of the Department of Obstetrics and
Gynaecology, and the Department of Oncology, Helsinki University Central Hospital,
Finland. All index patients and family members donating blood samples signed a written
informed consent.
2 Patients and families (I-IV)
BRCA1 and BRCA2 mutation-positive Finnish families included in Studies I and II had been
identified at the University Hospitals of Helsinki, Kuopio, Oulu, and Tampere (Vehmanen et
al., 1997a, 1997b; Huusko et al., 1998; Syrjäkoski et al., 2000; Vahteristo et al., 2001). In
Study I, 34 BRCA1 and 37 BRCA2 mutation-positive families were examined for breast and
ovarian cancer phenotypes (Table 4). Families with recurrent BRCA1/BRCA2 mutations
(n=55) were studied for mutation-associated haplotype conservation (I, II). The number of
families with each recurrent mutation is indicated in Table 4. In addition to the Finnish
families, 18 Icelandic families with the BRCA2 999del5 mutation were included in Study II.
The Icelandic families had been identified by the research group of Dr. R. B. Barkardóttir at
the University Hospital of Iceland. For comparison of the mutation-associated haplotypes
between Finnish and Swedish BRCA1 3744delT families, and between Finnish and Austrian
BRCA1 5370C→T families, samples from four Swedish families identified by Zelada-
Hedman et al. (1997) and from one Austrian family identified by Wagner et al. (1998) were
included in Study I.
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Table 4. Number of Finnish BRCA1/BRCA2 mutation-positive families studied for breast and ovarian
cancer phenotypes (I), and mutation-associated haplotype conservation (I, II), as well as mutations
screened and methods used in mutation screening of unselected ovarian carcinoma patients (III) and
ovarian carcinoma families (IV).
Gene and mutation Mutation
type
No. of families
included in the
phenotype
analysis (I)
No. of families
included in the
haplotype
analysis
(I or II)d
Screened in 233
unselected
ovarian
carcinoma
patients (III)
Screened in
23 ovarian
carcinoma
families (IV)
BRCA1
Ex 11, 1806C→T Nonsense - - No Yese
Ex 11, 1924delA Frameshift 1 - Yesf Yese
Ex 11, 2803delAAa Frameshift 2 - Yese Yese
Ex 11, 3264delT Frameshift - - Yese Yese
Ex 11, 3604delA Frameshift 5 5 (I) Yesf Yese
Ex 11, 3744delTb Frameshift 7 7 (I) Yesf Yese
Ex 11, 3904C→A Nonsense 1 - Yesf Yese
Ex 11, 4153delAc Frameshift 1 - Yesf Yese
Int 11, 4216nt-2A→G Splice site 9 8 (I) Yesf Yese
Ex 13, 4446C→T Nonsense 3 3 (I) Yese Yese
Ex 17, 5145del11 Frameshift 1 - Yesg Yese
Ex 20, 5370C→T Nonsense 3 2 (I) Yese Yese
Ex 20, 5382insC Frameshift 1 - Yese Yese
Total 34 Total 25
BRCA2
Ex 9, 999del5 Frameshift 13 10 (II) Yesg Yese
Ex 11, 4081insA Frameshift 1 - Yese Yese
Ex 11, 5797G→T Nonsense - - Yesf Yese
Ex 11, 6495delGCA→C Frameshift 1 - Yese Yese
Ex 11, 6503delTT Frameshift 3 2 (I) Yese Yese
Ex 15, 7708C→T Nonsense 8 7 (I) Yese Yese
Ex 18, 8555T→G Nonsense 4 4 (I) Yesf Yese
Int 23, 9346nt-2A→G Splice site 7 7 (I) Yesf Yese
Total 37 Total 20 (I),
and 10 (II)
ex, exon; int, intron; aAlso known as 2804delAA (the BIC database); bAlso known as 3745delT (the BIC
database); cAlso known as 4154delA (the BIC database);dThe recurrent BRCA1 2803delAA mutation was not
included in the haplotype analysis as no samples were available; Mutation detection was performed by eallele-
specific oligonucleotide (ASO) hybridization, frestriction fragment length polymorphism (RFLP) analysis, or
gagarose gel electrophoresis
In Study III, the prevalence of BRCA1 and BRCA2 mutations was studied in 233
unselected Finnish ovarian carcinoma patients who belonged to a cohort of 573 epithelial
ovarian carcinoma patients treated at the Department of Obstetrics and Gynaecology,
Helsinki University Central Hospital, Finland, during 1989–1998. Blood samples were
collected from the patients in 1997 and 1998 in conjunction with routine check-up visits that
occur at least once a year for a time period of 10 years after the initial treatment. At the end of
the year 1998, 220 of the 573 patients were alive, and the study cohort covered 91% of the
patients who were alive during the study period.
In Study IV, BRCA1 and BRCA2 mutations were screened in 23 Finnish ovarian
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carcinoma families with at least two cases of epithelial ovarian carcinoma in first-degree
relatives. The families had been identified in a population-based study on cancer incidence in
first-degree relatives of Finnish ovarian carcinoma patients as described by Auranen et al.
(1996b). Briefly, all women with epithelial ovarian carcinoma diagnosed from 1980 to 1982
who were under the age of 76 years were selected from the FCR (n=863). The first-degree
relatives of these patients were identified through local parish registers and from the
Population Register Centre, and information on their cancer diagnoses was obtained from the
FCR. Data on all first-degree relatives was obtained for 559 women, 27 of which had at least
one first-degree relative with epithelial ovarian carcinoma. Formalin-fixed, paraffin-
embedded tumour and normal tissue blocks from cancer patients belonging to these 27
families had been collected from different hospitals and pathology laboratories. For
BRCA1/BRCA2 mutation analyses, samples were available from 51 individuals belonging to
23 of these 27 families. Of these 51 individuals, 41 had ovarian carcinoma, five had breast
cancer, and five had some other cancer (borderline ovarian cancer, melanoma, or cancer of
the bladder or pancreas). Additionally, blood samples were available from three sisters with
epithelial ovarian carcinoma and from their healthy brother. Fourteen of the families were
site-specific ovarian carcinoma families: 11 with two affected cases, and three with three
affected cases; breast cancer was present in nine families.
3 Previously identified BRCA1 and BRCA2 germline mutations studied here (I-IV)
The previously identified BRCA1 and BRCA2 mutations analysed in Studies I-IV are
indicated in Table 4 (Vehmanen et al., 1997a, 1997b; Huusko et al., 1998; Syrjäkoski et al.,
2000; Vahteristo et al., 2001).
4 Collection of cancer and genealogical data (I-IV)
For Study I, information on breast and ovarian cancer diagnoses and ages at onset in the 34
BRCA1 and 37 BRCA2 mutation-positive families was obtained by family questionnaires and
from hospital records and death certificates. All female breast and ovarian cancer cases in
first- and second-degree relatives were included in the phenotype analysis, except for those
who were known not to be BRCA1 or BRCA2 mutation carriers.
For the 55 Finnish families that were studied for mutation-associated haplotype
conservation (I, II), genealogical data (extending preferentially at least to grandparents or
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great-grandparents of the index patients) were obtained by interviewing the index patients
and through church parish registers and the Population Register Centre. For the 18 Icelandic
families studied for 999del5 mutation-associated haplotype conservation (II), pedigree data
were obtained from the Icelandic Genetic Council at the University Hospital of Iceland, and
cancer diagnoses were verified through the Department of Pathology, University Hospital of
Iceland, and from the Icelandic Cancer Registry.
For the 233 unselected ovarian carcinoma patients (III), information on age at ovarian
carcinoma diagnosis, FIGO stage, tumour histology, and grade were collected from hospital
records. In case of inconsistency in the information, tumour specimens obtained from
different hospitals and pathology laboratories were reviewed for tumour histology and grade.
Distribution of clinical and tumour characteristics in our study cohort and in the general
Finnish ovarian carcinoma patient population are shown in Table 5. Information on other
cancers in index patients and on cancer cases in the first- and second-degree relatives of the
index patients were collected by questionnaire interviews.
For the 23 Finnish ovarian carcinoma families (IV), information on cancer diagnoses of
the index patients and their first-degree relatives had been obtained from the FCR (Auranen
et al., 1996b). The FIGO stage, tumour histology, grade, and ploidy were extracted from a
study by Auranen et al. (1997).
Table 5. Clinical and tumour characteristics of the 233 unselected ovarian carcinoma
patients (III) and of the general ovarian carcinoma patient population.
Variable Our study cohort
(n=233)
General ovarian
carcinoma patient
populationa
Stage available 133 (57%)
I 60 (45%) 27%
II 8 (6%) 13%
III 57 (43%) 47%
IV 8 (6%) 13%
Grade available 155 (67%)
1 69 (44%) 27%
2 38 (25%) 20%
3 48 (31%) 53%
Histology available 233 (100%)
Serous 118 (51%) 45%
Mucinous 49 (21%) 13%
Endometrioid 33 (14%) 10%
Mesonephroid 19 (8%) 9%
Poorly differentiated 14 (6%) 23%
Mean+SD age at ovarian
carcinoma diagnosis, range
55+13 years,
23–96 years
58+13 years
SD, standard deviation; aAccording to the study by Venesmaa (1994)
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5 Extraction of DNA (I-IV)
Genomic DNA was extracted from blood leucocytes using standard phenol-chloroform
methods (I-IV) and from formalin-fixed, paraffin-embedded tumour and normal tissue blocks
(IV) according to the protocol described by Isola et al. (1994).
6 Genotyping (I, II)
For genotyping of the 25 Finnish families carrying recurrent BRCA1 mutations, 11
polymorphic microsatellite markers spanning a genetic interval of 26 cM around BRCA1
were used (I). Markers and their genetic map distances (cM) are shown in Figure 2a [Weber
et al., 1990; Futreal et al., 1992; Feunteun et al., 1993; Albertsen et al., 1994; Dib et al., 1996;
Murrell et al., 1997; the Genome Database (GDB); National Center for Biotechnology
Information (NCBI)]. Sequences of the PCR primers were obtained from the GDB. The PCR
products were labelled with [α-32P]deoxycytidine triphosphate (dCTP) (DuPont/NEN),
electrophoresed on denaturing 7% polyacrylamide gels, and visualized by exposing the gels
to autoradiography. Allele sizes were determined by the M13mp18 marker (Sequenase kit,
United States Biochemical) on each gel.
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Figure 2. Marker order and map distances in centiMorgans (cM).
a) Markers used in genotyping of the Finnish BRCA1 mutation-positive families (I).
b) Markers used in genotyping of the Finnish BRCA2 mutation-positive families; all 24 markers were
used in genotyping of the families with the 999del5 mutation (II), while markers indicated by an
asterisk (n=17) were used in genotyping of the families with other recurrent BRCA2 mutations (I).
c) Markers used in genotyping of the Icelandic BRCA2 999del5 mutation-positive families (II); all 28
markers were used in genotyping of the five large, high-risk breast cancer families, while five markers
indicated by an asterisk were used in genotyping of the 13 pairs of sisters with breast cancer.
cen, centromere; ex, exon; tel, telomere; THRA1, avian erythroblastic leukemia viral (v-erb-a)
oncogene homolog
For genotyping of the 30 Finnish BRCA2 families (I, II), polymorphic markers spanning
a genetic interval of 36 cM around BRCA2 were used; 24 markers were used for the 10
families with the 999del5 mutation (II), and 17 markers were used for the 20 families with
other recurrent BRCA2 mutations (I) (Figure 2b) (Couch et al., 1996; Dib et al., 1996;
Généthon; the GDB; NCBI). For marker loci D13S260 through D13S267, marker order and
physical distances were determined using the genomic sequence of this region (the Sanger
Centre), and PCR primer sequences were positioned with Sequencher v3.0 (Gene Codes
Corporation). The physical distances were converted to genetic distances assuming 1 cM =
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0.5 megabases (Mb), which was the observed average recombination ratio at this region. In a
haplotype analysis of recurrent BRCA2 mutations, Neuhausen et al. (1998) used an
assumption of 1 cM = 0.67 Mb between marker loci D13S290 and D13S267, which is similar
to the ratio used here. For the other markers, map distances were obtained from Généthon
(NCBI). Primer sequences for all other D13S markers except D13S1696, which was obtained
from Couch et al. (1996), were obtained from the GDB. For the SLS markers, primer
sequences were kindly provided by Dr. M Stratton. Genotyping was carried out with a
fluorescent technique using an ABI377 instrument according to instructions provided by
Applied Biosystems. Allele sizes were matched based on the Centre d’Etude du
Polymorphisme Humain (CEPH) reference individual 1347-02 (Applied Biosystems), which
was used as a control on each gel. Genotype data were analysed by GeneScan v3.1 and
Genotyper v2.0 software (Applied Biosystems).
For genotyping of the 18 Icelandic families with the BRCA2 999del5 mutation (II),
polymorphic markers covering a 29 cM interval around BRCA2 were used (Figure 2c) (Couch
et al., 1996; Dib et al., 1996; Généthon; the GDB; NCBI). Of the 18 Icelandic families, five
were large, high-risk breast cancer families and 13 were pairs of sisters diagnosed with breast
cancer by the age of 60 years. For genotyping of the five large families, 28 markers were
used, while for genotyping of the families with an affected sister pair, five of these markers
were used (Figure 2c). Primer sequences, as well as marker order and map distances, were
obtained as described above. Genotyping was carried out using the protocol described by
Barkardottir et al. (1995). For direct comparison of allele sizes between the Finnish and
Icelandic 999del5 mutation-positive families, a few mutation carriers from the Icelandic
families were genotyped using the same technique used for Finnish families.
To estimate the corresponding marker allele frequencies in the general Finnish and
Icelandic populations, 42 and 96 Finnish population controls were genotyped for markers
within and flanking the BRCA1 and BRCA2 genes, respectively, and 50 Icelandic population
controls were genotyped for markers within and flanking the BRCA2 gene. To estimate the
population prevalence of the Icelandic 999del5 core haplotype, 14 Icelandic parents-child
control trios were genotyped.
7 Haplotype construction (I, II)
The haplotypes within the families were constructed with the Genehunter program (Kruglyak
et al., 1996). The haplotypes were proofread and some were reconstructed manually due to
Genehunter’s limited capability to assign haplotypes in families with complex structure. If the
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mutation-associated haplotype could not be constructed in a family (when samples were not
available from several family members), genotypes were compared with the mutation-
associated haplotypes of the other families with the same mutation. The history of
recombinations between the families was reconstructed by assuming minimum diversity of
haplotypes; by starting from the site of the mutation and moving outwards in both directions,
historical recombinations were noted as the branching of the haplotype when two or more
different alleles were observed for a marker, thus creating a haplotype reconstruction tree.
8 Detection of BRCA1 and BRCA2 germline mutations (III, IV)
8.1 Screening for previously identified mutations (III, IV)
8.1.1 Allele-specific oligonucleotide (ASO) hybridization (III, IV)
In the ASO hybridization method, two ASO probes, one for the mutated sequence and
another for the wild-type sequence, are designed for each mutation. Mutation detection is
based on appropriate hybridization conditions in which only the probe that is a perfect match
will anneal to PCR-amplified DNA sequences (Saiki et al., 1986). The ASO hybridization
protocol described by Friedman et al. (1995) was used to screen for known BRCA1/BRCA2
mutations in unselected ovarian carcinoma patients (III) and in ovarian carcinoma families
(IV). The mutations that were screened using ASO are indicated in Table 4. Briefly, genomic
DNA was amplified by PCR, and PCR products were denatured, transferred to nylon filters
(DuPont/NEN) using a 96-well dot-blot vacuum apparatus (Bio-Dot SF, Bio-Rad), and fixed
by exposure to ultraviolet light. Two filters were prepared for detection of each mutation: one
for hybridization of the probe with the wild-type sequence and the other for the hybridization
of the probe with the mutated sequence. The 18-bp-long ASO probes were designed such that
the mutation site was located in the middle of the probe [GenBank identification numbers for
BRCA1 and BRCA2 cDNA sequences: U14680 and U43746, respectively (NCBI)]. The
probes were end-labelled with [α-32P]dCTP (DuPont/NEN) using terminal transferase
enzyme (Boehringer Mannheim) according to the manufacturer’s instructions. Hybridization
reactions were carried out at 54oC in a rotating hybrization oven (Thermo Hybaid). After
prehybridization (30–60 min), the ASO probes were added to hybridization solutions, and
after incubation (3–4 h), the filters were washed and exposed to X-ray films at -80oC for 3–18
h.
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8.1.2 Restriction fragment length polymorphism (RFLP) analysis (III, IV)
RFLP analysis is based on the creation or destruction of a restriction enzyme cleavage site by
a mutation (Botstein et al., 1980). Here, RFLP was used to screen for nine of the known
BRCA1/BRCA2 mutations in unselected ovarian carcinoma patients (III) (Table 4). In Study
IV, RFLP was used to confirm mutations that had been detected by ASO. Briefly, genomic
DNA was amplified by PCR, PCR products were digested with appropriate restriction
enzymes (Table 6), and digestion products were analysed on 3% ethidium bromide stained
agarose gels. The RFLP analyses were designed such that incomplete digestion would lead to
a false-positive result, hence minimizing the possibility of a false-negative result.
Table 6. Restriction endonucleases and respective digestion conditions for the detection
of BRCA1 and BRCA2 mutations by RFLP.
Mutations
BRCA1 BRCA2
Enzymes Digestion conditions
1924delA, 3744delT, 3904C→A Tsp509Ia 65oC, 16 h
3604delA, 4153delA MboIIa 37oC, 1 h
4216nt-2A→G 8555T→G MseIa 37oC, 16 h
5797G→T NlaIIIa 37oC, 16 h
9346nt-2A→G BfmIb 37oC, 16 h
RFLP, restriction fragment length polymorphism; aNew England Biolabs; bMBI Fermentas
8.1.3 Agarose gel electrophoresis (III)
Mutations that were deletions of several base pairs, i.e., BRCA1 5145del11 and BRCA2
999del5, were detected using agarose gel electorophoresis. Genomic DNA was amplified by
PCR, and PCR products were run on 3% ethidium bromide stained agarose gels.
8.2 Scanning for novel mutations (III)
8.2.1 Protein truncation test (PTT) (III)
In PTT, modified forward primers that contain a T7 RNA polymerase promoter sequence and
an eukaryotic translation initiation sequence are used in PCR, and proteins are synthesized in
a coupled in vitro transcription/translation reaction and analysed by gel electrophoresis (Roest
et al., 1993). Here, PTT was used to screen for protein-truncating mutations in BRCA1 exon
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11 and BRCA2 exons 10 and 11 in 38 ovarian carcinoma patients (III), who reported (1) two
or more first- or second-degree relatives diagnosed with breast and/or ovarian cancer, (2) one
first-, second-, or third-degree relative with ovarian cancer, or (3) one first-degree relative
with breast cancer, or with both breast and ovarian cancer, and/or had themselves been
diagnosed with both cancers. BRCA1 exon 11 was amplified in three partly overlapping
fragments, BRCA2 exon 10 was amplified in one fragment, and BRCA2 exon 11 was
amplified in five partly overlapping fractions with previously published primers (Hogervorst
et al., 1995; Friedman et al., 1997). The PTT reactions were carried out using the TNT® T7
Coupled Reticulocyte Lysate System (Promega) according to the manufacturer’s instructions,
with [35S]methionine (Amersham Biosciences) as a radioactive label. The proteins were run
on 12.5% sodium dodecyl sulphate polyacrylamide gels and visualized by exposing the dried
gels to X-ray films at -80oC for 4–72 h.
8.2.2 Southern blot hybridization (III)
Southern blot hybridization can be used to study large genomic rearrangements,
amplifications, or deletions with sequence-specific probes (Southern, 1975). Southern
analysis using BRCA1 specific probes was performed on 11 ovarian carcinoma patient
samples and two healthy population control individuals (III) according to the protocol
published by Petrij-Bosch et al. (Petrij-Bosch et al., 1997; the BIC database) with slight
modifications (III). Briefly, genomic DNA (5 µg) was completely digested with EcoRI
restriction enzyme (New England Biolabs), separated on an 0.8% agarose gel, denatured, and
transferred onto a nylon membrane (Hybond-N+, Amersham Biosciences). The hybridization
probes were obtained by amplifying cloned, full-length BRCA1 cDNA (pcBRCA1-385, a kind
gift from Dr. L Brody) in three partly overlapping regions with primers published in the
original article (III), and by labelling purified PCR products with [α-32P]dCTP
(DuPont/NEN) using Rediprime DNA labelling system according to instructions provided by
Amersham Biosciences. Hybridizations were performed at 65oC in a rotating hybrization
oven (Thermo Hybaid); after prehybridization (40–60 min), denatured probes were added to
hybridization solutions, and after incubation (over night), the filters were washed and
exposed to autoradiography film at -80oC for 16–18 h.
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8.3 Direct sequencing (III, IV)
Mutations detected by ASO, RFLP, or agarose gel electrophoresis were confirmed by direct
sequencing using an ABI Prism 310 Genetic Analyser and Dye Terminator Cycle Sequencing
Ready Reaction Kit according to instructions provided by Applied Biosystems. All samples
with varying bands in PTT were sequenced as well. For direct sequencing, samples were
reamplified from genomic DNA.
9 Statistical methods (I-IV)
9.1 General (I, III, IV)
Variation in the age at breast and ovarian cancer diagnosis was analysed by unpaired t-test (I,
IV). Fisher’s exact test and χ2 test were used (1) to compare the proportions of ovarian
carcinoma between BRCA1 and BRCA2 mutation-positive families (I), (2) to study the
correlation between the location of the mutation (5´ versus 3´ end of the gene) and the
proportion of ovarian carcinoma in BRCA1 mutation-positive families (I), (3) to examine the
association between BRCA1/BRCA2 mutation carrier status and young age (<50 years) at
breast cancer diagnosis (III), and (4) to determine associations between mutation carrier status
and various clinicopathological parameters of ovarian carcinomas (IV). All p-values were
two-sided. The cumulative age-specific percentages of age at diagnosis for breast and ovarian
cancer were determined using five-year intervals for the BRCA1 and BRCA2 mutation-
positive families, as well as for the general Finnish breast and ovarian cancer patient
populations (the FCR, 1997) (I).
9.2 Luria-Delbrück equation (I, II)
The number of generations (g) elapsed from a common ancestor for the BRCA1/BRCA2
families with the same haplotype was estimated by modifications of the Luria-Delbrück
equation (Luria and Delbrück, 1943; Lehesjoki et al., 1993)  of pexcess = α(1 – θ)g, where α = 1
(all chromosomes carry the same mutation), and θ refers to the recombination fraction
between the gene/mutation and the marker locus. In the previous modifications of the Luria-
Delbrück equation (Lehesjoki et al., 1993; Hästbacka et al., 1994; Höglund et al., 1995),
pexcess = (paffected – pnormal)/(1 – pnormal) denoted the excess of an allele at a marker locus among
51
mutation-associated chromosomes versus normal population chromosomes. Here, mutation-
associated haplotype reconstruction trees were used to derive pexcess-values. Two
modifications were used: in the first one (modification 1), population allele frequencies were
taken into consideration and pexcess was defined as pexcess = (paffected – pnormal)/(1 – pnormal),
while in the other one (modification 2) pexcess was assumed equal to paffected. Modification 2
was used to achieve minimum and maximum estimates for time elapsed from a common
ancestor, and paffected-values were calculated at each marker either as the fraction of different
haplotype variants carrying the allele present in the most common haplotype variant
(minimum estimate) or as one of the alleles observed in different haplotype variants
(maximum estimate). Modification 1 was used to calculate minimum estimates only, and
pnormal denoted the frequency of the allele present in the most common mutation-associated
haplotype variant in normal population chromosomes. In Studies I and II, slightly different
versions of modification 1 were used; the paffected-value was calculated either as the fraction of
different haplotype variants (II) or as the fraction of families (I) carrying the allele present in
the most common haplotype variant. The average of the values obtained at different markers
was considered as the most likely time estimate in each calculation.
9.3 Logistic regression (III)
Logistic regression analysis was used to determine the odds of mutation for unselected
ovarian carcinoma patients (III); the X variable was the presence or absence of
BRCA1/BRCA2 mutation, and personal and family histories of breast and ovarian cancer were
used as explanatory variables.
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RESULTS
1 Studies on recurrent BRCA1 and BRCA2 mutations (I, II)
1.1 Mutation-associated haplotypes
In haplotype analyses, all Finnish families carrying the same BRCA1 or BRCA2 mutation
were found to share a common core haplotype, except for those with the BRCA2 999del5
mutation (Figure 3). For the 999del5 mutation, two distinct core haplotypes were seen: a rare
one (haplotype A) was shared by three families, while a more common haplotype (haplotype
B) was present in seven families. Finnish families with haplotype A shared a four-marker
haplotype with Icelandic 999del5 mutation-positive families (Figures 3 and 4). The lengths of
the shared core haplotypes varied widely (1.6 to 26 cM) between families with different
mutations (Figures 3 and 4, and Table 7). The haplotype shared between the Icelandic and
Finnish 999del5 mutation-positive families extended approximately 0.5 cM centromeric to
the mutation site.
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Figure 3. Mutation-associated haplotype reconstruction trees of the Finnish families with
BRCA1/BRCA2 founder mutations. In each figure, the order of markers studied and their map
distances in centiMorgans (cM) from the gene/mutation are shown on the left. For each mutation,
haplotype reconstruction tree shows the minimum number of historical recombinations between the
families and the core haplotype shared by the families. Family numbers are indicated in italics. For the
Swedish families with the 3744delT mutation, family numbers begin with the S letter. In 999del5
mutation-associated haplotype A, the allele sizes shared between the Finnish and Icelandic families
with the same mutation are presented in boldface; in family 158, a four-marker haplotype (164-184-
225-157) at marker loci D13S1698, SLS163, D13S1697, and SLS329 was shared, while in families
102 and 6003 a three-marker haplotype (184-225-157) was shared at marker loci SLS163, D13S1697,
and SLS329. In haplotype A, the two different allele sizes seen at marker locus D13S1698 are likely to
be due to a mutation (Weber and Wong, 1993) or a null allele (Callen et al., 1993). cen, centromere;
ex, exon; tel, telomere; THRA1, avian erythroblastic leukemia viral (v-erb-a) oncogene homolog; *,
ambiguous allele; –, unknown allele
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Figure 4. BRCA2 999del5 mutation-associated haplotype reconstruction tree of the Icelandic families.
The order of markers studied and their map distances in centiMorgans (cM) from the mutation are
shown on the left. The reconstruction tree shows the minimum number of historical recombinations
between and within the families and the core haplotype shared between all the families. Family
numbers are indicated in italics, and the numbers separated by colons from the family numbers refer
to individuals whose haplotypes have diverged from the main haplotype seen in the family. All 28
markers were used in genotyping the five large, high-risk breast cancer families (2F, 4, 5A/B, 6, 7A/C),
and the five markers indicated with an asterisk were used in genotyping the 13 families in which two
sisters had been diagnosed with breast cancer (2, 10, 13, 15, 16, 21, 23, 24, 32, 51, 57, 59, and 67).
Nine different haplotype variants, each of which is indicated with a distinct symbol, were identified in
the families based on the extent of haplotype sharing between marker loci D13S220 and D13S1246,
which are marked in boldface. In families 5A/B and 7A/C, two different haplotype variants were seen
in each, and for sister pairs 57 and 59, the haplotype variant remained uncertain due to missing data
on markers centromeric to the mutation. The nine different haplotype variants differed in frequency:
the most common variant was present in 6 families, while 6 variants were seen in only one family
each. A four-marker haplotype (1-1-1-1) indicated with boldface at marker loci D13S1698, SLS163,
D13S1697, and SLS329 was shared between the Icelandic and Finnish families with haplotype A. cen,
centromere; ex, exon; tel, telomere; –, unknown allele
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1.2 Estimated number of generations from a common ancestor for families sharing a
conserved core haplotype
The estimated number of generations (g) elapsed from a common ancestor for the families
sharing a conserved core haplotype was calculated with modifications of the Luria-Delbrück
equation when at least four families had the same core haplotype (Table 7). Here, families
carrying the BRCA1 3604delA mutation were an exception, as the five families shared an odd
haplotype extending 15.5 cM telomeric and 0 cM centromeric to the BRCA1 gene (Figure 3),
which did not allow us to make any estimations of time elapsed from a common ancestor.
Modifications 1 and 2 gave consistent results (Table 7); in most cases, the time estimates
obtained using modification 1 were within the minimum and maximum estimates obtained
using modification 2.
Table 7. Estimated number of generations elapsed from a common ancestor for families sharing a
conserved core haplotype.
Estimated number of generations (g) and years (y)
elapsed from a common ancestor for familiesa,
(No. of data points used in the calculations)
Gene and mutation,
(No. of families)
Length of the
shared
haplotype (cM)
Modification 1b Modification 2c
BRCA1
3604delA (5) 15.5 - -
3744delT
Finnish families (7) 1.6 28 g; 560–700 y (8) 24–32 g; 480–800 y (8)
Finnish (7) and Swedish (4)
families
1.6 30 g; 600–750 y (8) 23–36 g; 460–900 y (8)
4216nt-2A→G (8) 15 < 10 g; < 250 y (2) 9 g; 180–225 y (2)
4446C→T (3) 7.9 - -
5370C→T (2) 26 - -
BRCA2
999del5
Finnish families
with haplotype B (7) 6 6 g; 120–150 y (4) 7–12 g; 140–300 y (8)
with haplotype A (3) 3.2 - -
Icelandic families (18) 1.7 21 g; 420–525 y (6) 16–40 g; 320–1000 y (9)
6503delTT (2) 9.8 - -
7708C→T (7) 2.7 13 g; 260–325 y (6) 10–20 g; 200–500 y (10)
8555T→G (4) 3.2 7 g; 140–175 y (6) 7–9 g; 140–225 y (8)
9346nt-2A→G (7) 3.2 11 g; 220–275 y (5) 7–10 g; 140–250 y (8)
s
cM, centiMorgan; g, generations; y, years; aSome additional unpublished data is presented; bThe pexcess-value of
the Luria-Delbrück equation: pexcess = α(1 – θ)g, was defined as pexcess = (paffected – pnormal)/(1 – pnormal); cThe
pexcess-value of the Luria-Delbrück equation: pexcess = α(1 – θ)g, was assumed equal to paffected; the minimum and
maximum estimates were obtained by calculating the paffected-value as the fraction of different haplotype variants
carrying the allele present in the most common haplotype variant and as one of the alleles observed in different
haplotype variants, respectively
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1.3 Geographical origins of the families
Plotting of the birthplaces of parents, grandparents, or great-grandparents of the index
patients on the map of Finland revealed distinct geographical clustering of the origins of
BRCA1/BRCA2 mutation-positive families (Figure 5).
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BRCA1 3744delT BRCA1 4216nt-2A>G
BRCA1 5370C>T
BRCA2 8555T>G
BRCA1 4446C>T
BRCA2 9346nt-2A>G
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Figure 5. Maps of Finland showing the origins of BRCA1 and BRCA2 mutation-positive families.
Circles indicate birthplaces of grandparents or great-grandparents of the index patients. Squares
represent birthplaces of the parents of the index patients, and triangles represent birthplaces of the
index patients, which were marked when no information on previous generations was available. The
lengths of the shared haplotypes in centiMorgans (cM) are also indicated.
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2 Breast and ovarian carcinoma phenotypes of BRCA1 and BRCA2 mutation carriers
(I)
The number of female breast and ovarian carcinoma cases and the mean age at breast and
ovarian carcinoma diagnosis for each mutation are presented in Table 8. Altogether, 87
female breast carcinoma cases and 46 ovarian carcinoma cases were identified in the 34
BRCA1 families, which is on average 2.6 breast and 1.4 ovarian carcinoma cases per family.
In the 37 BRCA2 families, there were 123 female breast carcinoma cases, 1 male breast
carcinoma case (with the 999del5 mutation and diagnosed at age 47 years), and 21 ovarian
carcinoma cases, which is on average 3.3 female breast and 0.6 ovarian carcinoma cases per
family. The proportion of ovarian carcinoma was significantly higher, with a 2.4-fold
difference, in the BRCA1 mutation-associated families than in the BRCA2 mutation-
associated families (p<0.001, χ2 test).
Table 8. Number of breast and ovarian cancer cases and the mean age at breast and ovarian cancer
diagnosis for each mutation.
Gene and mutation No. of
families
included in
phenotype
analysis (I)
No. of
female
breast
cancer
cases
No. of female
breast cancer
cases for which
age at diagnosis
was available
(mean age at
diagnosis, y)
No. of
ovarian
cancer
cases
No. of ovarian
cancer cases
for which age
at diagnosis
was available
(mean age at
diagnosis, y)
BRCA1
Ex 11, 1924delA 1 1 1 (44) - -
Ex 11, 2803delAA 2 3 3 (56) 2 2 (62)
Ex 11, 3604delA 5 7 7 (45) 10 9 (46)
Ex 11, 3744delT 7 7 7 (45) 10 9 (49)
Ex 11, 3904C→A 1 3 3 (49) 3 2 (59)
Ex 11, 4153delA 1 1 1 (32) 1 1 (48)
Int 11, 4216nt-2A→G 9 24 23 (43) 8 8 (52)
Ex 13, 4446C→T 3 23 19 (46) 8 8 (53)
Ex 17, 5145del11 1 4 4 (37) - -
Ex 20, 5370C→T 3 12 12 (49) 3 2 (67)
Ex 20, 5382insC 1 2 2 (57) 1 1 (40)
Total 34 87 82 (46) 46 42 (51)
BRCA2
Ex 9, 999delTCAAA 13 52 43 (47) 6 5 (60)
Ex 11, 4081insA 1 2 2 (67) 2 2 (60)
Ex 11, 6495delGCA→C 1 3 3 (52) - -
Ex 11, 6503delTT 3 8 3 (57) 4 4 (62)
Ex 15, 7708C→T 8 26 24 (45) 4 3 (56)
Ex 18, 8555T→G 4 12 12 (49) 1 1 (60)
Int 23, 9346nt-2A→G 7 20 19 (52) 4 4 (66)
Total 37 123 106 (48) 21 19 (61)
ex, exon; int, intron; y, years
61
A statistically significant correlation was present between the location of the mutation
and the breast and ovarian carcinoma phenotype in BRCA1 mutation-associated families; the
proportion of ovarian carcinoma was significantly higher (p<0.001, χ2 test), with a 2.3-fold
difference, in families carrying mutations in exon 11 as compared with those with mutations
towards the 3´ of this exon.
The distribution of ages at breast cancer diagnosis was similar in BRCA1 and BRCA2
mutation-associated families (mean+SD, 45.6+11.6 years vs. 48.4+13.7 years; range, 22–73
years vs. 25–95 years) (Figure 6a), while the mean+SD age at ovarian carcinoma diagnosis
was significantly younger in the BRCA1 mutation-associated families than in those with
BRCA2 mutations (51.3+9.2 years vs. 61.2+9.7 years; range, 38–77 years vs. 45–78 years;
p<0.001, unpaired t-test). In the BRCA1 families, ovarian carcinoma had been diagnosed
before the age of 50 years in almost 60% of cases; the corresponding percentages were less
than 20% for the BRCA2 mutation-associated cases and less than 30% for the general ovarian
carcinoma patient population (Figure 6b).
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Figure 6. Cumulative age-specific percentages of age at diagnosis for (a) breast and (b) ovarian
cancer in the BRCA1 and BRCA2 mutation-associated families, and in the general Finnish breast and
ovarian cancer patient populations (i.e., all breast and ovarian cancer cases diagnosed in Finland
during 1995) (the FCR, 1997).
3 BRCA1 and BRCA2 germline mutations in unselected Finnish ovarian carcinoma
patients (III)
3.1 Mutations detected
A germline mutation in BRCA1 or BRCA2 was found in 5.6% (13/233) of the unselected
Finnish ovarian carcinoma patients; 11 patients (4.7%) were BRCA1 mutation-positive and
two (0.9%) were BRCA2 mutation-positive. The mutations detected are presented in Table 9.
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All 13 mutation-positive patients were carriers of the previously identified Finnish
BRCA1/BRCA2 mutations, and seven recurrent founder mutations accounted for 12 of the 13
mutations detected. The only unique mutation had been identified previously in a patient that
also belonged to the present study cohort.
Table 9. Mutations detected and personal and family history of breast and ovarian carcinoma of the
mutation carriers.
Patient
no.
Gene and
mutationa
Type of
cancer and
age at
diagnosis (y)
No. of 1st- and 2nd-degree
relatives with breast and/or
ovarian cancer (type of
cancer, age at diagnosis, and
degree of relatedness)
Bc at
any
agee
Bc and
oc in the
same
womanf
Bc
<50 yf
Bc and oc
in the
same
woman
and/or bc
<50 yf
BRCA1
654 3604delAb Bc 41, oc 44 Yes Yes Yes Yes
911 3604delAb Oc 42 1 (bc 55, 2nd) Yes No No No
913 3604delAb Oc 42 1 (bc 46, 1st) Yes No Yes Yes
1000 3604delAb Oc 53 2 (bc 58, oc 46, 1st; bc 50, 2nd) Yes Yes No Yes
816 3744delTb Oc 43 No No No No
673 4153delAb Bc 32, oc 48 Yes Yes Yes Yes
723 4216nt-2A→Gc Oc 59 No No No No
883 4216nt-2A→Gc Bc 52, oc 58 1 (bc n.k., 1st) Yes Yes No Yes
87 4446C→Td Bc 48, oc 58 3 (bc 52, 1st; 2x bc n.k., 2nd) Yes Yes Yes Yes
656 4446C→Td Bc 37, oc 40 Yes Yes Yes Yes
257 5370C→Td Bc 50, oc 57 1 (bc 60, 1st) Yes Yes No Yes
BRCA2
488 5797G→Td Oc 52 2 (bc d37, 1st; oc 55, 1st) Yes No Yes Yes
983 9346nt-2A→Gc Oc 70 1 (bc 43, 1st) Yes No Yes Yes
11/13
(85%)
7/13
(54%)
7/13
(54%)
10/13
(77%)
bc, breast cancer; d, deceased; n.k., not known; oc, ovarian cancer; y, years; aAll mutations detected in the present study had
been identified previously in the Finnish population (Vehmanen et al., 1997a, 1997b; Vahteristo et al., 2001), and all but
4153delA in BRCA1 are recurrent founder mutations; bFrameshift mutation; cSplice site mutation; dNonsense mutation; eIn the
index patient and/or her first- or second-degree relative(s); fIn the index patient or a first-degree relative
3.2 Personal and family history of breast and ovarian carcinoma of the mutation carriers
Personal and family history of breast and ovarian carcinoma of the 13 mutation-positive
patients is shown in Table 9; 11 patients (85%) had a personal and/or family history of breast
carcinoma, and in seven cases (54%) breast and ovarian carcinoma had been diagnosed in the
same woman. Furthermore, seven of the mutation-positive patients had a history of breast
carcinoma diagnosed before the age of 50 years. The diagnosis of both breast and ovarian
carcinoma in the same woman and/or young age (<50 years) at breast cancer diagnosis was
characteristic of most (77%) mutation carriers. In the BRCA1 mutation-associated families,
the mean+SD age at ovarian carcinoma diagnosis was 49.2+7.3 years (range 40–59 years) and
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the mean+SD age at breast carcinoma diagnosis was 47.6+8.9 years (range 32–60 years) (in
the index patients and their first-degree relatives). Except for one mesonephroid carcinoma,
all BRCA1/BRCA2 mutation-associated ovarian carcinomas were of serous or poorly
differentiated histology.
3.3 Relationship between mutation carrier status and personal and family history of breast
and ovarian carcinoma
In the logistic regression analysis, the single most significant predictor of a BRCA1 or BRCA2
germline mutation was the presence of both breast and ovarian cancer in the index patient or
a first-degree relative (Table 10). The odds ratio also independently increased for patients
with at least two first- or second-degree relatives with breast or ovarian carcinoma, and for
patients with one first- or second-degree relative with breast carcinoma only (Table 10).
Notably, no mutations were detected in the 13 ovarian carcinoma patients who reported one
first- or second-degree relative with ovarian carcinoma only. In patients with a history of
breast carcinoma diagnosed before the age of 40 (n=4) or 50 (n=13) years, BRCA1/BRCA2
mutations were found in 75% and 54% of the patients, respectively, while mutation
frequencies were lower in patients with a history of breast carcinoma diagnosed after the age
of 50 (n=10) or 60 (n=4) years: 30% and 0%, respectively. The association between mutation
carrier status and young age (<50 years) at breast carcinoma onset was, however, not
statistically significant (p=0.40, Fisher’s exact test).
Table 10. Logistic regression analysis of the association between personal and family history of
breast and ovarian cancer and BRCA1/BRCA2 mutation carrier status.
Variable Coefficient SE OR (95% CI)
Intercept -4.21 0.59 0.02 (0.01–0.05)
Breast and ovarian cancer in the same persona 4.59 0.99 98.69 (14.11–690.15)
Family history of breast and ovarian cancerb
One relative with breast cancer 1.83 0.85 6.22 (1.17–33.16)
One relative with ovarian cancer -3.00 6.20 0.05 (2.65 x 10-7–9402.47)
Two or more relatives with breast or ovarian cancer 2.70 1.16 14.84 (1.53–143.61)
CI, confidence interval; OR, odds ratio; SE, standard error; aIndex or a first-degree relative; bIn first- or second-
degree relatives
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4 BRCA1 and BRCA2 germline mutations in Finnish ovarian carcinoma families (IV)
4.1 Mutations detected
A germline mutation in BRCA1 or BRCA2 was detected in 5 of the 23 (22%) Finnish families
with at least two cases of ovarian carcinoma in first-degree relatives (Table 11). Two of the
families were BRCA1 mutation-positive and three were BRCA2 mutation-positive. In one
family, a novel, apparently disease-causing BRCA2 missense mutation 8702G→A in exon 21,
leading to conversion of glycine to aspartate at codon 2901, had been identified in a previous
study (Roth et al., 1998). We considered this alteration to be a disease-associated mutation, as
it has not been detected in 220 cancer-free Finnish control individuals and is located within
an evolutionally conserved region of the protein (Roth et al., 1998); thus, altogether 26%
(6/23) of the 23 Finnish ovarian carcinoma families were BRCA1 or BRCA2 mutation-
positive.
Table 11. Mutations identified in the families and clinicopathological characteristics of the ovarian
carcinomas.
Ovarian carcinomaFamily and
patient no.
Gene and
mutation
Type of
cancer
Age at
diagnosis (y) Histology Stage Grade DNA ploidy
BRCA1
Family 36
36-1 1806C→Ta Ovarian 39 Undifferentiated III 3 A
36-4 1806C→Ta Ovarian 56 Serous III 3 A
36-5 1806C→Ta Ovarian 39 Undifferentiated III 3 A
Family 29
29-1 3744delTb Ovarian 53 Undifferentiated I 3 A
29-4 3744delTb Ovarian 49 Undifferentiated III 3 D
29-5 3744delTb Ovarian 38 n.d. n.d. n.d. n.d.
BRCA2
Family 10
10-1 7708C→Ta Ovarian 73 Endometrioid III 2 A
10-4 7708C→Ta Ovarian 63 Transitional III 1 D
Family 30
30-1 9346nt-2A→Gc Ovarian 54 Serous III 3 A
30-3 n.d. Ovarian 48 n.d. n.d. n.d. n.d.
30-4 9346nt-2A→Gc Breast 45
Family 33
33-1 9346nt-2A→Gc Ovarian 51 Clear cell III 3 A
33-4 Mutation-negative Ovarian 68 Serous III 3 A
Family 19
19-1 8702G→Ad Ovarian 59 Transitional III 3 A
19-4 8702G→Ad Ovarian 58 Serous III 1 A
19-5 8702G→Ad Ovarian 55 Endometrioid I 2 A
A, aneuploid; D, diploid; n.d., not defined; y, years; aNonsense mutation; bFrameshift mutation; cSplice site mutation;
dMissense mutation; the mutation had been previously identified in family 19 by Roth et al. (1998), and it is designated as
8930G→A in the BIC database.
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4.2 Characteristics of mutation-positive and -negative ovarian carcinoma families
Breast carcinoma was present in only one of the mutation-positive families, and that case had
been diagnosed at the age of 45 years, whereas all eight families with later-onset breast
carcinoma (range, 51–75 years; mean+SD, 61.4+8.0 years) were mutation-negative. Of the 14
site-specific ovarian carcinoma families included in the study, all three with three affected
individuals were mutation-positive, while mutations were found in only 18% (2/11) of the
families with two ovarian carcinoma cases only. In the carriers of BRCA1 mutations, the
mean age at ovarian carcinoma diagnosis was 12 years younger than in the BRCA2 mutation
carriers (45.7+8.0 years vs. 57.6+7.8 years; p=0.016, unpaired t-test) or in the BRCA1/BRCA2
mutation-negative patients (45.7+8.0 years vs. 57.5+8.3 years, p=0.002, unpaired t-test). All
the BRCA1 mutation-associated carcinomas were of undifferentiated histology, except for one
serous carcinoma, whereas carcinomas of the BRCA2 mutation carriers and non-carriers were
of various histological subtypes. Most BRCA1 and BRCA2 mutation-associated tumours
(80% and 86%, respectively) were of stage III, and all BRCA1 mutation-associated tumours
were of high grade. However, with regard to stage or grade, neither BRCA1 nor BRCA2
mutation-associated tumours differed significantly from non-BRCA1/2 mutation-associated
tumours (Fisher’s exact test; stages I and II, and III and IV were combined, and grades 1 and
2 were combined). Aneuploid tumours were more frequent in BRCA1 (80%) and BRCA2
(86%) mutation carriers than in non-carriers (31%), and the difference was statistically
significant between the BRCA2 mutation-associated cases and non-carriers (p=0.026; Fisher’s
exact test).
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DISCUSSION
1 Studies on recurrent BRCA1 and BRCA2 mutations (I, II)
Eleven BRCA1/BRCA2 mutations have been found to account for the vast majority of all
BRCA1/BRCA2 mutations identified in the screening of the entire coding regions of the genes
(Vehmanen et al., 1997a, 1997b; Huusko et al., 1998). Here, we studied ancestral origins and
geographical distribution of families carrying these recurrent mutations. We found that the
birthplaces of the parents and grandparents of index patients were clustered in distinct
geographical regions of Finland, and all carriers of the same recurrent mutation, except for
those with the BRCA2 999del5 mutation, shared a common core haplotype, suggesting that
these mutation alleles are identical by descent, i.e., founder mutations. In the 999del5
mutation-positive families, two distinct core haplotypes were seen, which may be due to gene
conversion. This is supported by the geographical clustering of the families as well as by the
population history of Finland. Nevertheless, the possibility that the same mutation has arisen
twice cannot be ruled out. The lengths of the shared haplotypes varied widely (1.6 to 26 cM)
between families with different mutations, and the estimates of time elapsed from a common
ancestor for the families varied accordingly. For families sharing the shortest core haplotype
of 1.6 cM, the common ancestor was estimated to date back 24–32 generations (i.e., 480–800
years), while for families with a long 15 cM haplotype, the corresponding time was estimated
to be less than 10 generations (i.e., <250 years).
Birthplaces of the grandparents of index patients carrying the BRCA1 3604delA
mutation clustered in the southern, coastal region of the country, and as the mutation has also
been reported in Dutch, Belgian, and German families (Peelen et al., 1997; the BIC database),
it likely was brought into Finland from Central Europe, across the Baltic Sea. The clustering
of grandparents’ birthplaces in a very restricted area and the long haplotype of 15.5 cM
shared by the families suggest that these families had a common ancestor fairly recently. No
estimate of time elapsed from a common ancestor was obtained due to the odd haplotype
shared by the families.
The BRCA1 3744delT mutation (also known as 3745delT) has not been reported in
countries other than Finland and Sweden (Zelada-Hedman et al., 1997; the BIC database).
The Finnish and Swedish families studied here shared a short haplotype of 1.6 cM and were
estimated to have had a common ancestor 23–36 generations (i.e., 460–900 years) ago. The
common origin of the families is further supported by the low (0.57%) estimated frequency of
the haplotype in the Finnish population. In Finland, the grandparents’ birthplaces clustered in
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Northern Ostrobothnia, although some were located in Southern and Central Finland.
According to church records, the majority of the Finnish families with this mutation have
been living in Ostrobothnia for at least 300 years, while the Swedish families clustered on the
opposite side of the Gulf of Bothnia. As the Swedish crusade to Finland began in the 12th
century, and massive colonization activity from Sweden to the southwest of Finland and to
the coast of Ostrobothnia occurred in the 12th and 13th centuries (Jutikkala and Pirinen, 1996),
the mutation might well have been introduced into the Finnish population by Swedish
colonists. Our estimate of the time elapsed from a common ancestor for the families (460–
900 years) is in accordance with these historical records.
The BRCA1 4216nt-2A→G mutation is unique to the Finns and the most frequently
observed BRCA1 mutation in Finland thus far (detected in 10 families). The birthplaces of the
grandparents were found to be enriched in Central and Northern Ostrobothnia, and this
regional concentration and the long 15 cM common haplotype suggest that the families had a
common ancestor recently. Our estimate of time elapsed since a common ancestor was less
than 10 generations (i.e., <250 years).
The BRCA1 mutations 4446C→T and 5370C→T were both clustered in Karelia. The
three Finnish families with the 4446C→T mutation shared a long haplotype of 7.9 cM, and in
the two 5370C→T mutation-positive families, the common haplotype extended over the
entire area of 26 cM studied. The numbers of families were, however, too small for time
estimations, but the long shared haplotypes and the regional clustering of parents’ and
grandparents’ birthplaces suggest that these families had a common ancestor fairly recently.
The 4446C→T mutation has been reported several (52) times in the BIC database and has
been identified in families of Dutch, Belgian, French, French Canadian, British, and North
American ancestry (Neuhausen et al., 1996; Stoppa-Lyonnet et al., 1997; Szabo and King,
1997; Tonin et al., 1998; the BIC database). The Finnish 4446C→T mutation-positive
families have been found to share a three-marker haplotype with French, French Canadian,
Dutch, and Belgian families, indicating that the mutation carriers may have a common
ancient origin (Dr. J Simard, personal communication). However, in France, some families
with the this mutation have a different common haplotype, and still another haplotype is seen
in British 4446C→T mutation-positive families, suggesting that the mutation may have arisen
de novo several times (Friedman et al., 1995; Neuhausen et al., 1996; Dr. J Simard, personal
communication). The 5370C→T mutation has been reported in Germany, Austria, and the
US (Wagner et al., 1998; Meindl and German Consortium for Hereditary Breast and Ovarian
Cancer, 2002). The Finnish families were observed to share a long haplotype of 10 cM with
the Austrian family included in the study. The mutation alleles may thus be identical by
descent in Finland and Austria, which is supported by the low estimated frequency (0.006%)
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of the haplotype in the Finnish population.
The BRCA2 mutation 6503delT has been reported several (39) times in the BIC
database, and Swedish, Dutch, Belgian, British, American, and Canadian families have been
described to carry this mutation (Neuhausen et al., 1998; the BIC database). In Finland, it has
been identified in three families, and grandparents’ birthplaces were located in the late
settlement region, in Northern Karelia and in Northern Ostrobothnia. The Finnish families
shared a long 9.8 cM haplotype, the alleles of which were completely different from those
seen in haplotypes described elsewhere (Neuhausen et al., 1998), suggesting that the same
mutation is likely to have independent origins in different populations. The Finnish families
seem to have had a common ancestor quite recently, but as the number of families studied
was small, estimation of the time elapsed from a common ancestor was not possible.
For the BRCA2 7708C→T mutation, the birthplaces of the parents and grandparents
were scattered in the south-eastern part of the country and around Lake Ladoga. The fairly
wide distribution of the origins of the families, mainly in the area of early settlement,
excluding the coast of Bothnia, and the short (2.7 cM) identical haplotype in the mutation
alleles suggest that the common ancestor is distantly located and the mutation may have
spread from the Savo-Karelia region into the more western parts of the country. The time
from a common ancestor was estimated to date back 10–20 generations (i.e., 200–500 years).
Interestingly, the same mutation has been reported in a family of Asian ancestry but has not
been reported elsewhere (the BIC database).
The BRCA2 8555T→G mutation has not been reported in countries other than Finland,
the families with this mutation being clustered in a restricted area in Pirkanmaa and sharing a
haplotype of 3.2 cM. The number of generations from a common ancestor was estimated to
date back 7–9 generations (i.e., 140–225 years). This situation of families sharing a short
common haplotype and clustering in a restricted area in the early settlement region might
reflect the subisolate structure of the Finnish population that persisted until the Second World
War (Nevanlinna, 1972; Norio et al., 1973).
The birthplaces of the grandparents of the index patients with the BRCA2 9346nt-
2A→G mutation are located in Karelia and in Northern Finland. The mutation may have been
introduced into the area of late settlement during the internal migration movement that started
in the 16th century mainly with settlers from South Savo (Nevanlinna, 1972; Norio et al.,
1973). The families shared a 3.2 cM haplotype and were estimated to have had a common
ancestor 7–11 generations (i.e., 140–275 years) ago. This mutation is the most common
BRCA1/BRCA2 mutation identified in Finland (detected in 14 families) and has also been
reported in a Czech family but not elsewhere (the BIC database).
The surprising finding of two distinct core haplotypes (a 3.2 cM haplotype A in three
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families, and a 6 cM haplotype B in seven families) in Finnish families with the BRCA2
999del5 mutation may be due to gene conversion. Although very little is currently known
about gene conversion in humans, it has been proposed to be quite frequent and the major
factor contributing to the decay of LD over short distances (Frisse et al., 2001; Przeworski
and Wall, 2001). The hypothesis that the two distinct Finnish 999del5 mutation-associated
haplotypes are due to gene conversion is supported by the geographical distribution of the
birthplaces of the parents and grandparents of index patients and by the population history of
Finland. Families with haplotype A, as well as those with haplotype B, clustered in the same,
restricted area in the early settlement region (in Pirkanmaa, Satakunta, and Southern
Ostrobothnia), and families with haplotype B formed another cluster in Northern Karelia, in
the late settlement region. The mutation may thus have originally arisen on haplotype A,
being then transferred to haplotype B by gene conversion. The mutation in association with
haplotype B could have been brought into Karelia when the inhabitation of the eastern and
northern parts of the country began in the 16th century by internal population movements
from the early settlement area (Nevanlinna, 1972; Norio et al., 1973). The common ancestor
of the families with the more common haplotype B was estimated to date back 6–12
generations (i.e., 120–300 years), but the number of families with haplotype A was too small
for time estimations. Previously, a similar situation has been described in Finland; a mutation
in the transglutaminase 1 gene, causing autosomal recessive congenital ichtyosis, has been
observed on two distinct haplotypes, both of which are clustered in the early settlement
region in Savo, and one of them also in Central Finland (Laiho et al., 1997).
In Iceland, the 999del5 mutation is the only BRCA2 mutations identified and has been
detected in the majority (67%) of breast cancer families with multiple affected members
(Gudmundsson et al., 1996; Thorlacius et al., 1996). The 18 Icelandic families/sister pairs
studied here shared a short conserved haplotype of 1.7 cM, and the common ancestor of the
families was estimated to date back to 16–40 generations (i.e., 320–1000 years). According to
historical records, Iceland was settled mainly by Vikings from Western Scandinavia and the
British Isles during the 9th–11th centuries (Rafnsson, 1999; Sawyer, 1999). The mutation may
thus have been brought into Iceland as early as during the settlement of the country.
Interestingly, Finnish families with haplotype A shared allele sizes with Icelandic families at
four markers spanning approximately 0.5 cM centromeric to the mutation site. This shared
haplotype appears to be rare in both populations, supporting the possibility of a common
ancient origin of the Finnish and Icelandic 999del5 mutation-positive families; the estimated
frequency of the four-marker haplotype was 1.3% and 2.2% in Finnish and Icelandic
populations, respectively, and the actual frequency of a two-marker haplotype available (164-
225 at loci D13S1698 and D13S1697) in 102 normal Finnish chromosomes was 2.0%
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(estimated frequency 4.3%) and that of a three-marker haplotype available (1-1-1 at loci
D13S1698, SLS163, and SLS329) in 28 normal Icelandic chromosomes was 3.6% (estimated
frequency 10.0%). The ancient 999del5 mutation may have been introduced into the Finnish
and Icelandic populations during different time periods and been preserved in these
populations due to random genetic drift. For the same reason, the mutation may have been
lost in some populations where it was also introduced. If the 999del5 mutation alleles are
identical by descent in the Finnish and Icelandic families, then the common ancestor must
date back considerably further than to the time since the mutation was introduced into the
Icelandic population. Although the Finnish and Icelandic 999del5 mutation-positive families
may have a common ancient origin, and the two distinct haplotypes seen in the Finnish
families may due to gene conversion, the same mutation arising de novo more than once
cannot be ruled out. Short symmetric elements have been proposed to predispose DNA
sequences to meiotic microdeletions (Schmucker and Krawczak, 1997), and three such
elements partially overlap or closely flank the 999del5 mutation site. The 999del5 mutation
has been reported a few times elsewhere, in families of Latin American/Caribbean, Native
American/Central European/Northern European, and English origin (the BIC database).
Furthermore, three other short deletions have been identified in this region: 995delCA,
995delCAAAT, and 1002delAA (Mavraki et al., 1997; Schubert et al., 1997; the BIC
database), suggesting that the site might represent a mutational hot spot. Thus, the common
ancient origin of the 999del5 mutation in Finland and Iceland remains uncertain.
It is worth noting that haplotype analysis does not give an estimate of the time elapsed
since a mutation started to spread in a population, but it does allow estimation of the time
elapsed since there was a common ancestor for the families included in the study.
Furthermore, time estimates based on the extent of LD or shared haplotypes in a relatively
small number of mutation chromosomes are by necessity rough and subject to variation, as
the small sample size leaves the number of detected recombinations sensitive to chance.
Moreover, LD is a complex phenomenon affected not only by physical distance but also by
the distance from the centromere (Watkins et al., 1994) and the presence of recombination
hot spots (Jeffreys et al., 2001) and suppression regions (Liu and Barker, 1999; Jorde, 2000).
According to recent studies, the human genome is organized into discrete blocks of limited
haplotype diversity extending up to 100 kb, but interpopulation differences in the sizes of the
blocks have been observed (Daly et al., 2001; Patil et al., 2001; Reich et al., 2001). These
haplotype blocks have only a few (2–4) haplotypes, while greater haplotype diversity is seen
in regions spanning the blocks (Daly et al., 2001; Reich et al., 2001). The relationship
between LD and physical distance is further complicated by numerous other factors, such as
mutation, natural selection, gene flow, demographic history, stochastic events, and gene
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conversion (Laan and Pääbo, 1997; Zavattari et al., 2000; Pritchard and Przeworski, 2001).
LD has, however, been successfully used in isolated founder populations to localize disease
loci for specific rare monogenic diseases (Ozelius et al., 1992; de la Chapelle and Wright,
1998; Peltonen et al., 1999, 2000a). The advantage of such populations for mapping
susceptibility genes underlying complex diseases has been proposed to be less striking (Eaves
et al., 2000; Peltonen et al., 2000a; Altmüller et al., 2001), and the choice of populations for
LD mapping studies of complex disease are still open issues (Kruglyak, 1999; Wright et al.,
1999). Nevertheless, isolated founder populations may be more advantageous than admixed
ones in genetic studies of complex disorders because of reduced allelic and locus
heterogeneity. Homogeneity of environmental and cultural components is also a distinct
advantage for genetic studies (Peltonen et al., 2000a, 2000b). In addition, there is recent
evidence that small, isolated subpopulations exhibit higher levels of LD around common
alleles than the larger populations from which they are derived (Zavattari et al., 2000). The
multiple local founder effects and the long shared haplotypes (1.6 to 26 cM) around mutation
alleles underlying a multifactorial disease observed here provide support for the concept that
isolated founder populations with known demographic histories may offer definite
advantages for mapping novel susceptibility genes for multifactorial disorders. In Finland,
multiple small subisolates that remained relatively stable until the Second World War and
industrialization (Nevanlinna, 1972; Norio et al., 1973; Peltonen et al., 1999) may have
allowed random genetic drift to create allelic disequilibrium.
In isolated founder populations, reduction in genetic heterogeneity is illustrated by the
significant reduction of the number of mutations found in specific disease-related genes. For
example, among Icelanders, only one mutation has been identified in each of the BRCA1 and
BRCA2 genes (Thorlacius et al., 1997; Bergthorsson et al., 1998). Since BRCA1 and BRCA2
mutations do not affect the fitness of their carriers, their fate is not determined by natural
selection, and the striking difference in the observed BRCA1/BRCA2 mutation spectra in
Finland and Iceland (the total number of distinct BRCA1/BRCA2 mutations identified being
32 and 2, respectively) may reflect differences in the settling of these countries; Finland is
likely to have been inhabited continuously since the last glacial period around 10 000 years
ago by small immigrant groups (Jutikkala and Pirinen, 1996; Peltonen et al., 1999; Norio,
2000), while Iceland is believed to have been settled mainly by Vikings quite recently, during
the 9th–11th centuries (Rafnsson, 1999; Sawyer, 1999). In Finnish families with the HNPCC
syndrome, a large number (11) of different MLH1 mutations have also been identified, but
three common founder mutations account for more than 80% of all MLH1 mutation-positive
HNPCC families (Nyström-Lahti et al., 1995, 1996; Holmberg et al., 1998; Salovaara et al.,
2000).
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Since our studies on recurrent BRCA1 and BRCA2 mutations, a number of new families
have been found to carry the founder mutations studied here, and five more recurrent
mutations have been described: two in BRCA1 (1806C→T, and 5382insC), and three in
BRCA2 (4075delGT, 4081insA, and 5797G→T), bringing the total number of recurrent
mutations in Finland to 16 (Syrjäkoski et al., 2000; Vahteristo et al., 2001; III; IV;
unpublished data). Although a number of unique BRCA1 and BRCA2 mutations have been
identified as well, they seem to account for only a minority of all BRCA1/BRCA2 mutation-
positive families in Finland (unpublished data). In addition to 31 distinct protein-truncating
mutations and one missense mutation considered to be of clinical significance (8702G→A in
BRCA2), a number of common, benign variants have been described in each gene. The high
coverage of founder mutations of all BRCA1/BRCA2 mutations in Finland is of great
importance in clinical diagnostics of breast and/or ovarian carcinoma families, as
BRCA1/BRCA2 mutation carrier detection may be initiated with the screening of regions
where known mutations reside, and then, if no mutation is found, screening of the entire
coding regions may be required. In certain areas of Finland, BRCA1/BRCA2 mutation testing
is further facilitated by the specific and narrow mutation spectra. In contrast, in the capital
region of Helsinki, all Finnish BRCA1/BRCA2 mutations have been observed. The existence
of these founder mutations has also facilitated studies evaluating the prevalence of BRCA1
and BRCA2 germline mutations in various study populations in Finland: in unselected breast
(Syrjäkoski et al., 2000) and ovarian carcinoma (III) patients, and in ovarian carcinoma
families (IV).
2 Contribution of BRCA1 and BRCA2 germline mutations to ovarian carcinoma in
Finland (III, IV), and breast and ovarian carcinoma phenotypes of Finnish BRCA1 and
BRCA2 mutation carriers (I, III, IV)
Germline mutations of the BRCA1 and BRCA2 genes account for a varying fraction of
hereditary breast and ovarian carcinoma in different populations, and BRCA1/BRCA2
mutation spectra vary among populations as well (Szabo and King, 1997; Neuhausen, 1999).
Here, we detected a BRCA1 or BRCA2 germline mutation in 5.6% (13/233) of unselected
Finnish ovarian carcinoma patients (III), and among the Finnish ovarian carcinoma families,
the frequency of BRCA1/BRCA2 mutations was 26% (6/23) (IV). No novel mutations were
identified in Study III, and seven founder mutations accounted for 12 of the 13 mutations
detected, emphasizing the significance of BRCA1/BRCA2 founder mutations in Finland. In
Study IV, four different founder mutations accounted for the five mutation-positive families
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observed, and in one family, a novel, apparently disease-causing BRCA2 missense mutation
had been identified in a previous study by Roth et al. (1998). Large genomic rearrangements
of BRCA1 that have recently been identified in several breast/ovarian cancer families (Petrij-
Bosch et al., 1997; Puget et al., 1997, 1999; Swensen et al., 1997; Rohlfs et al., 2000; Unger
et al., 2000) and have also been described as major BRCA1 founder mutations in the
Netherlands (Petrij-Bosch et al., 1997) do not seem to be significant in the Finnish
population, as no such mutations were detected here (III) or in another study of 80 Finnish
breast and/or ovarian carcinoma families (Lahti-Domenici et al., 2001). The mutation
frequencies reported here illustrate the burden of the previously identified Finnish
BRCA1/BRCA2 mutations on Finnish ovarian carcinoma patients and families. Moreover, we
believe that our results provide good estimates of the actual impact of BRCA1/BRCA2
mutations in these patient groups since founder mutations appear to account for most
BRCA1/BRCA2 mutation in Finland (Vehmanen et al., 1997a, 1997b; Huusko et al., 1998;
unpublished data). Among unselected ovarian carcinoma patients, the real mutation
frequencies might, however, be somewhat higher, as BRCA1/BRCA2 mutation-associated
ovarian carcinomas are typically of advanced stage, and moderate to high grade (Rubin et al.,
1996; Aida et al., 1998; Boyd et al., 2000; Moslehi et al., 2000; Werness et al., 2000; Risch et
al., 2001; IV), but in our retrospectively collected study cohort, such tumours were slightly
underrepresented. Moreover, mucinous carcinoma were somewhat overrepresented in our
study cohort, while carcinomas of mucinous subtype appear to be very rare in BRCA1/BRCA2
mutation carriers (Boyd et al., 2000; Moslehi et al., 2000; Werness et al., 2000; Risch et al.,
2001; III; IV).
Germline mutations in BRCA1 and BRCA2 have been proposed to be sufficient to
explain the majority of hereditary ovarian carcinoma (Gayther et al., 1999; Antoniou et al.,
2000). Here, a BRCA1 or BRCA2 mutation was found in all three site-specific ovarian
carcinoma families with three affected cases, whereas most families (9/11) with only two
ovarian carcinomas were mutation-negative (Roth et al., 1998; IV). Similarly, among the
unselected ovarian carcinoma patients (III), all 13 patients who reported one first- or second-
degree relative with ovarian carcinoma only were mutation-negative. Our findings are in line
with reports from other populations; in British families with two ovarian carcinoma cases in
first- or second-degree relatives, BRCA1/BRCA2 mutations were found in only 20%, while
mutations were detected in 70% of families with at least three cases of ovarian carcinoma and
no more than one case of breast carcinoma (Gayther et al., 1999). Furthermore, a study
consisting of French, British, and American families has suggested that the vast majority of
site-specific ovarian carcinoma families with at least three affected family members are
carriers of BRCA1 germline mutations (Steichen-Gersdorf et al., 1994). Most ovarian
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carcinoma families without BRCA1/BRCA2 mutations may be explained by incomplete
sensitivity of mutation detection, chance clustering of sporadic cases, and non-genetic
familial factors (Gayther et al., 1999; Antoniou et al., 2000). Additionally, germline
mutations in the genes involved in the HNPCC syndrome may account for a small proportion
of BRCA1/BRCA2 mutation-negative ovarian carcinoma families (Rubin et al., 1998).
However, in some families, germline mutations in yet unknown ovarian cancer-susceptibility
genes, possibly with lower penetrance, may be present (Sutcliffe et al., 2000).
In contrast to ovarian carcinoma, where germline mutations of BRCA1 and BRCA2
appear to explain the majority of hereditary cases (Gayther et al., 1999; Antoniou et al.,
2000), only a minority of hereditary breast carcinomas seem to be due to BRCA1/BRCA2
germline mutations, and evidence suggests that other still undiscovered breast cancer-
susceptibility genes also exist (Serova et al., 1997; Ford et al., 1998; Kainu et al., 2000;
Antoniou et al., 2001; Cui et al., 2001; Eerola et al., 2001a). In Finnish families with at least
three cases of breast or ovarian carcinoma in first- or second-degree relatives, the frequency
of BRCA1/BRCA2 mutations was only 5% among site-specific breast carcinoma families,
while in families with both breast and ovarian carcinoma, 50% were found to be mutation-
positive (Vahteristo et al., 2001). In line with this, the frequency of BRCA1/BRCA2 mutations
was considerably higher in unselected Finnish ovarian carcinoma patients (5.6%) (III) than in
unselected Finnish breast carcinoma patients (1.8%) (Syrjäkoski et al., 2000).
Most hereditary ovarian carcinomas have been suggested to be due to mutations in
BRCA1, while the contribution of BRCA2 mutations to ovarian carcinoma has been proposed
to be smaller (Ford et al., 1998). Accordingly, we found a significantly higher proportion of
ovarian carcinoma in Finnish families with BRCA1 mutations than in those with BRCA2
mutations (I). Also among unselected ovarian carcinoma patients, BRCA1 mutations were
considerably more frequent than mutations in BRCA2 (4.7% and 0.9%, respectively) (III). In
contrast, among unselected Finnish breast carcinoma patients, the reverse was observed
(BRCA1 and BRCA2 mutation frequencies being 0.4% and 1.4%, respectively) (Syrjäkoski et
al., 2000). The frequencies of BRCA1 and BRCA2 mutations among unselected ovarian
carcinoma patients vary considerably between populations (for BRCA1 between 2% and 27%,
and for BRCA2 between 0% and 14%) (Johannesdottir et al., 1996; Takahashi et al., 1996;
Stratton et al., 1997; Berchuck et al., 1998; Rubin et al., 1998; Janezic et al., 1999; Tonin et
al., 1999; Anton-Culver et al., 2000; Moslehi et al., 2000; Tobias et al., 2000; van der Looij
et al., 2000; Risch et al., 2001; Smith et al., 2001; Khoo et al., 2002; Liede et al., 2002). The
highest BRCA1/BRCA2 mutation frequencies have been described among Ashkenazi Jews
(25–41%) (Moslehi et al., 2000; Tobias et al., 2000) and Pakistanis (16%) (Liede et al.,
2002). In the Icelandic population, approximately 8% of unselected ovarian carcinoma
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patients are carriers of the BRCA2 999del5 mutation (Johannesdottir et al., 1996).
Frequencies similar to the ones observed here have been reported in admixed British and
American populations (2–9% for BRCA1, and 1–3% for BRCA2) (Stratton et al., 1997;
Berchuck et al., 1998; Rubin et al., 1998; Janezic et al., 1999; Anton-Culver et al., 2000;
Smith et al., 2001).
For genetic couselling purposes, it is important to identify clinical risk factors that
could best predict the presence of a BRCA1/BRCA2 mutation in a family so that diagnostic
mutation screening could be directed to potential mutation carrier families. Among the
unselected Finnish ovarian carcinoma patients, the most significant predictor of a
BRCA1/BRCA2 mutation was the presence of both breast and ovarian carcinoma in the same
patient (III). Furthermore, family history of breast carcinoma was strongly related to mutation
carrier status. We also found that BRCA1/BRCA2 mutation frequencies were higher among
patients who had a history of early onset breast carcinoma (<40 or <50 years) as compared
with those with a history of breast carcinoma diagnosed at a later age (>50 years). The
number of breast cancer cases for which information on the age at onset was available was,
however, small, and no statistically significant association between mutation carrier status
and young age (<50 years) at breast cancer onset was observed (III). In the phenotype analysis
of the 71 Finnish BRCA1/BRCA2 mutation-positive families (I), young age at breast cancer
diagnosis was characteristic for both BRCA1 and BRCA2 mutation carriers; more than 60% of
breast carcinomas in BRCA1 and BRCA2 mutation carriers had been diagnosed before the age
of 50 years, while in the general breast cancer patient population, the corresponding
proportion was only about 25%. Among Finnish breast cancer families with at least three
breast or ovarian cancers in first- or second-degree relatives, the strongest predictors of a
BRCA1 or BRCA2 mutation are age of the youngest breast cancer patient and number of
ovarian cancer cases in the family (Vahteristo et al., 2001). In contrast to the present study
(III), the occurrence of both breast and ovarian carcinoma in the same woman was not an
independent predictor of a BRCA1/BRCA2 mutation in the study of Vahteristo et al. (2001),
probably because it is closely associated with ovarian carcinoma cases overall. In addition to
the number of breast and ovarian cancer cases in a family and the age at breast cancer onset,
the number and relationship of unaffected family members, along with their current ages or
ages at death, are taken into consideration in several models developed to estimate the
probability that a BRCA1 or BRCA2 mutation is present in a family (Berry et al., 1997;
Parmigiani et al., 1998; Schmidt et al., 1998).
In the phenotype analysis of the 71 Finnish BRCA1/BRCA2 mutation-positive families,
the age at ovarian carcinoma onset was significantly younger in families with BRCA1
mutations than in those with BRCA2 mutations (I); in the BRCA1 families, almost 60% of the
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ovarian carcinomas had been diagnosed before the age of 50 years, whereas in the BRCA2
families, the corresponding proportion was less than 20% (I). The distribution of ages at
diagnosis of ovarian carcinoma was similar in the BRCA2 mutation carriers and in the general
Finnish ovarian carcinoma patient population (I). Several other studies have also reported that
BRCA1 mutation-associated ovarian carcinomas are diagnosed on average at a younger age
than sporadic ones, while for BRCA2 mutation-associated ovarian carcinomas, the mean age
at ovarian cancer onset does not differ from that of sporadic patients (Boyd et al., 2000;
Moslehi et al., 2000; Risch et al., 2001; IV). Furthermore, the proportion of ovarian cancer
has been suggested to vary according to the location of the mutation in BRCA1 and BRCA2
(Gayther et al., 1995, 1997b; Risch et al., 2001; Thompson and Easton, 2001, 2002). Here,
we observed that in the BRCA1 mutation-positive families with mutations in exon 11, the
proportion of ovarian carcinoma was significantly higher than in the families carrying
mutations 3´ of this exon (I). This is supported by other studies that report a tendency for
BRCA1 families with mutations towards the 3´ end of the gene to have a lower than average
proportion of ovarian cancer cases (Gayther et al., 1995; Risch et al., 2001; Thompson and
Easton, 2002). In BRCA2, mutations located in the OCCR have been found to be associated
with a higher ratio of ovarian cancer to breast cancer than mutations located outside this
region (Gayther et al., 1997b; Thompson and Easton, 2001). The relationship between the
location of the mutation within or outside the OCCR and the proportion of ovarian carcinoma
could not be studied here as only a few families carried mutations located within the OCCR
defined by Gayther et al. (1997b).
Studies on cancer risks in BRCA1/BRCA2 mutation-positive families have reported
similar estimates of breast cancer risk for both BRCA1 and BRCA2 mutation carriers (35–
87% and 26–84%, respectively, by the age of 70 years), but higher ovarian carcinoma risks
for BRCA1 mutation carriers as compared with BRCA2 mutation carriers (26–66% for
BRCA1 mutation carriers versus 9–27% for BRCA2 mutation carriers by age 70) (Ford et al.,
1994, 1998; Easton et al., 1995; Narod et al., 1995; Schubert et al., 1997; Thorlacius et al.,
1998; the BCLC, 1999; Warner et al., 1999; ABCSG, 2000; Antoniou et al., 2000, 2002;
Satagopan et al., 2001). Nevertheless, the risk of ovarian carcinoma in BRCA2 mutation
carriers is still considerable. Interestingly, we observed BRCA2 mutations in four and BRCA1
mutations in two of the 23 Finnish ovarian carcinoma families (IV), and none of the BRCA2
mutations were located within the suggested OCCR (Gayther et al., 1997b; Thompson and
Easton, 2001). In Finnish families with at least three cases of breast or ovarian carcinoma in
first- or second-degree relatives, the cumulative risk of subsequent ovarian cancer for breast
cancer patients by the age of 70 years has been reported to be 29% in BRCA1 and 8% in
BRCA2 mutation-positive families (Eerola et al., 2001a). However, by the age of 80 years, the
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risk reaches approximately 30% for both BRCA1 and BRCA2 mutation carriers, and the
higher relative risk of subsequent ovarian cancer for BRCA1 mutation carriers [standardized
incidence ratio (SIR) 61 vs. 38] has been attributed to the earlier onset of ovarian cancer in
BRCA1 mutation-associated families (Eerola et al., 2001a).
Apart from age, no significant differences in clinicopathological characteristics have
been reported between BRCA1 and BRCA2 mutation-associated ovarian carcinomas (Boyd et
al., 2000; Moslehi et al., 2000; Ramus et al., 2001; Risch et al., 2001). In our studies (III, IV),
all BRCA1 mutation-associated ovarian carcinomas, except for one, were of serous or
undifferentiated histology, while BRCA2 mutation-associated ovarian carcinomas were of
various histological subtypes. The number of BRCA1/BRCA2 mutation-associated ovarian
carcinomas was, however, small, and in larger studies, ovarian carcinomas of both BRCA1
and BRCA2 mutation carriers have been reported to typically be of serous histology (Rubin et
al., 1996; Aida et al., 1998; Boyd et al., 2000; Moslehi et al., 2000; Werness et al., 2000;
Risch et al., 2001). No carcinomas of mucinous subtype were seen among mutation carriers
(III, IV), and almost all BRCA1/BRCA2 mutation-associated carcinomas were of advanced
stage, and moderate to high grade (IV), which is in line with other reports (Rubin et al., 1996;
Aida et al., 1998; Boyd et al., 2000; Moslehi et al., 2000; Werness et al., 2000; Risch et al.,
2001). Aneuploid tumours were more frequent in BRCA1/BRCA2 mutation carriers than in
non-carriers (IV). Also in the study of Jóhannsson et al. (1997), four out of five BRCA1
mutation-associated ovarian carcinomas were aneuploid. In contrast to breast carcinoma,
where the histopathological phenotype has been suggested to be useful in predicting BRCA1
mutation carrier status (Eisinger et al., 1999; Cortesi et al., 2000; Lidereau et al., 2000), no
ovarian tumour characteristics have been found to be significant predictors of BRCA1/BRCA2
mutations.
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SUMMARY AND CONCLUSIONS
We examined ancestral origins and geographical distribution of Finnish families with
recurrent BRCA1/BRCA2 mutations. In addition, we studied breast and ovarian carcinoma
phenotypes of Finnish BRCA1 and BRCA2 mutation carriers and evaluated the prevalence of
BRCA1 and BRCA2 founder mutations in Finnish ovarian carcinoma patients and ovarian
carcinoma families. Our conclusions are as follows:
1) Carriers of the same recurrent BRCA1/BRCA2 mutation, except for those with the BRCA2
999del5 mutation, shared an identical core haplotype, indicating a common ancestor for
the families. In families with the 999del5 mutation, two distinct core haplotypes were
seen. Geographical clustering of the 999del5 mutation-positive families as well as the
population history of Finland support the hypothesis that the two distinct haplotypes are
due to gene conversion. The lengths of the shared core haplotypes varied widely (1.6 to
26 cM) between families with different mutations, and the estimates of time elapsed from
a common ancestor varied accordingly (6 to 32 generations). Finnish families with one of
the 999del5 mutation-associated haplotypes shared a 0.5 cM haplotype with Icelandic
families with the same mutation, which may indicate a common ancient origin for the
Finnish and Icelandic 999del5 mutation-positive families. However, distinct mutational
events cannot be ruled out.
2) In families with the founder mutations, birthplaces of the parents, grandparents, or great-
grandparents of index patients were found to be clustered within distinct geographical
areas of Finland. This facilitates BRCA1/BRCA2 mutation testing in certain regions where
the mutation spectra are still narrow.
3) The proportion of ovarian carcinoma was significantly higher in BRCA1 than BRCA2
mutation-positive families. Moreover, within BRCA1 families, the proportion of ovarian
carcinoma was significantly higher in families carrying mutations in exon 11 as compared
with those carrying mutations 3´ of this exon. The mean age at ovarian carcinoma onset
was significantly younger in families with BRCA1 mutations than in those with BRCA2
mutations (51 years vs. 61 years). For breast carcinoma, the distribution of ages at
diagnosis was similar in BRCA1 and BRCA2 mutation-positive families, and mutation
carriers were characterized by early age at diagnosis (mean, 46 years and 48 years).
Phenotypic characteristics associated with BRCA1 and BRCA2 germline mutations are
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important when deciding clinical management of mutation carriers.
4) Among unselected ovarian carcinoma patients, germline mutations of BRCA1 and BRCA2
were found in 4.7% and 0.9% of patients, respectively. The most significant predictor of a
BRCA1/BRCA2 mutation was the presence of both breast and ovarian carcinoma in the
same patient. In addition, family history of breast carcinoma in first- and second-degree
relatives was strongly related to mutation carrier status.
5) Germline mutations of BRCA1 and BRCA2 may account for most Finnish site-specific
ovarian carcinoma families with at least three affected cases. However, a minority of
families with only two ovarian carcinomas can be linked to BRCA1/BRCA2 germline
mutations. A significant fraction of the minor familial aggregation of ovarian carcinoma
may be explained by chance clustering of sporadic cases and by shared environmental
factors. Nevertheless, unidentified ovarian cancer-susceptibility genes, possibly with
lower penetrance, may also exist.
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